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Cardiovascular diseases were until recently the leading cause of death in Western
countries. It still is the number one cause of death in women. Even though malig-
nancies have a higher mortality rate, 27.2 % of all deaths in the Netherlands in 2012
were caused by cardiovascular events. In this group, death in men is most commonly
caused by a myocardial infarction. For women, this is caused by stroke.1
In the United States, cardiovascular diseases still have the highest mortality rate in
both men and women.2
Clinical relationship between ECAD and CAD events
Cardiovascular diseases are caused by atherosclerosis building up in the arteries and
narrowing the lumen (stenosis). This may lead to ischemia and infarction. Athero-
sclerosis is a gradual process, which increases with age. It already starts in childhood
with fatty streaks. The process of atherosclerosis development is shown in Figure 1.1.
Older people generally have a higher prevalence and severity of atherosclerosis. Be-
sides age, other risk factors of atherosclerosis are high blood pressure, diabetes, male
gender and high cholesterol. A familial predisposition, inactivity or obesity can also
inﬂuence the development of atherosclerosis. Less known risk factors are an increased
homocystein or high sensitive C-reactive protein (CRP) in the blood. There are a
number of predilection sites for atherosclerosis, of which the most common are the
coronary arteries, aorta, femoral arteries and carotid arteries.
The REACH trial revealed that one in every six patients with coronary artery disease
(CAD) or extra-cardiac arterial disease (ECAD) also had complaints of atherosclero-
sis in one or two other arterial territories.3 From these results it was concluded that
atherosclerosis is to be considered and treated as a systemic disease. A regional ex-
pression of atherosclerosis or diﬀering severity of disease might also be possible. Risk
factors, such as smoking and hypertension can inﬂuence for the general expression
of atherosclerosis, and on a more local scale, several promotors and inhibitors have
been discovered. For example in case of CAD, epicardial fat can play a possible role
in the development of atherosclerosis by paracrine eﬀects.4
A correlation has been found between low shear stress, turbulence or oscillating ﬂow
and plaque development.5 Therefore, low shear stress, which can cause gene modu-
lations of the endothelial cells, resulting in an increased oxidative stress, may also be
a possible promotor of rapid development of atherosclerosis. Areas with a laminar
ﬂow have a relatively small chance to develop atherosclerosis.5
How many and which other factors can evoke or suppress atherosclerosis is still sub-
ject to research. CAD and ECAD patients do not necessarily share a traditional risk
factor proﬁle, despite the common underlying disease.6
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The last decade research focus has been on identiﬁcation of as yet asymptomatic
patients with an increased to high risk of cardiovascular morbidity and mortality.
Several epidemiological studies have proposed diﬀerent formulas and risk scores to
predict cardiovascular morbidity and mortality. In patients with acute chest pain, but
without co-morbidity, the majority was free of CAD.7
Risk factors can only identify a minor part of patients who will suﬀer from a coronary
event in the future, and the presence of cardiac complaints also is also not clear.
On the other hand, ECAD is strongly associated with coronary and cerebral mor-
bidity and mortality.8 Prospective epidemiological studies in high risk patient groups
revealed a 20 - 60 % higher risk of a myocardial infarction and a 2 - 6 times greater
chance of cardiac-related death.9–11 Furthermore, the presence of CAD was found
to be 2.5 times higher in patients with ECAD, compared to those without.8 Patients
with peripheral arterial occlusive disease have a greater chance of a myocardial infarc-
tion than of a stroke, and these events are more often fatal.12,13 Even in a patient
population with a low incidence of CAD, there is a strong relationship between ECAD
and future coronary events.11
Imaging for coronary artery disease
Since the development of selective coronary catheter angiography (CAG) by Sones
in 1958, this technique has been the method of choice for detection and follow-up
of CAD. Several studies in the past have shown that diagnostic CAG has an average
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morbidity of 2 % and a mortality of approximately 0.1 %.14
New developments in medical imaging modalities have opened the way for non-
invasive coronary angiography by multi-detector computed tomography (MDCT) in
the last decade.15,16 Besides the lower complication risk and lower costs, MDCT also
has the advantage of vessel wall visualization. In this way, both the composition of
the plaque and its impact on the vessel lumen can be detected. A distinction can be
made between lipid, ﬁbrous and calciﬁed coronary plaques.17
In recent years it has become clear that plaque composition is a better risk-predictor
for acute coronary events than stenosis grade. Rupture of, so called, ‘vulnerable
plaques’ account for approximately 70 % of sudden coronary deaths. Although the
average absolute risk of severely stenotic plaques may be higher than that of average
absolute risk of mildly stenotic plaques, the last category overwhelmingly exceeds the
number of plaques with severe stenoses.18
In recent years, coronary computed tomography angiography (cCTA) has established
itself as an accurate non-invasive alternative to coronary angiography catheteriza-
tion. cCTA is excellent for detection of CAD, including both plaques and anatomical
stenosis. Both the sensitivity and negative predictive value of cCTA for coronary
stenosis are nearly 100 %. A challenge in cCTA is the suboptimal speciﬁcity. Calci-
ﬁed atherosclerotic plaques can obstruct the visualization of the coronary lumen and
quantiﬁcation of the degree of stenosis. This can lead to overestimation of the degree
of stenosis. Another issue, in both cCTA and invasive coronary angiography, is the
fact that anatomical stenoses do not necessarily cause ischemia. Evaluation of the
eﬀect of anatomical stenosis on myocardial perfusion is generally needed to diagnose
hemodynamically signiﬁcant CAD. The most frequently used method for perfusion
imaging is single photon emitting computed tomography (SPECT), whereas the most
accurate methods are adenosine perfusion magnetic resonance imaging (APMR) and
positron emission tomography (PET). APMR has the advantage of lack of radiation
and being more widely available.19
APMR is used to identify wall perfusion abnormalities of the left ventricle indicative
of myocardial ischemia. Perfusion abnormalities of the myocardium due to CAD oc-
cur early in the ischemic cascade, before the onset of symptoms, ECG-abnormalities
and wall motion disturbances. This makes the visualization of myocardial perfusion
relevant in a functional sense, and suitable for detecting early functional eﬀects of
coronary atherosclerosis. The increase in ﬂow through the coronary arteries relies
mostly on vasodilatation. Compensatory vasodilatation distal to a stenosis is able to
maintain ﬂow during rest, but during (pharmacologically induced) stress conditions
this capacity is exceeded. Adenosine induces vasodilatation of the coronary arteries.
Stenotic coronary arteries lack the capacity to further dilate, which creates a relative
area of hypoperfusion in the supplied myocardium compared to segments supplied by
normal coronary arteries.
Nuclear perfusion imaging techniques have been widely studied, and proven feasible
for perfusion imaging, but are limited by their spatial resolution, radiation burden,
the use of radioactive tracers and susceptibility to attenuation artifacts. MR has the
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ability to overcome these problems. First-pass perfusion MR imaging has also been
proven contributory in identifying segments with impaired perfusion and distinguishing
segments with diﬀerent degrees of obstruction. MR perfusion imaging with the use
of adenosine is routinely performed, the technique has been well described, and the
clinical indications published in a consensus panel report.20 First-pass perfusion MR
imaging has shown that it can identify regional reductions in full-thickness myocar-
dial blood ﬂow during global coronary vasodilatation over a wider range than SPECT
imaging. APMR has been shown to be an accurate and safe diagnostic modality to
assess myocardial ischemia and viability in patients with proven or suspected CAD.21
The problem of correlation between anatomical and functional (hemodynamically sig-
niﬁcant) information does not only exist for non-invasive imaging. Fractional ﬂow
reserve (FFR) is the only way to detect hemodynamic impact of a stenosis using
invasive coronary angiography: It measures the coronary blood pressures before and
after a stenosis. In case of a hemodynamically signiﬁcant stenosis, a decrease in
coronary blood ﬂow is seen, which gives an estimate for the severity of ischemia.
Recent developments in CT suggest that CT may provide an alternative method to
assess myocardial ischemia at some point in the future.22,23
Screening for coronary artery disease in extra-cardiac arterial
disease
Worldwide, cardiologists have set guidelines for the treatment of patients with car-
diac symptoms and related abnormalities. Flowcharts have been developed to help
physicians in the diagnostic process. Patient characteristics and the results of non-
invasive testing determine the need for therapy and/or further invasive testing. The
ﬁnding that a large proportion of patients in whom therapies are indicated do not
receive those therapies in actual clinical practice is discouraging.24
Until now CAG has been used to judge the degree of stenosis and determine the
need for revascularization. The role of cardiac CT and APMR imaging in the deci-
sion process is not yet established. For instance, no randomized clinical trials have
been performed to establish the value of cCTA in detecting left main stenosis eligi-
ble for surgery. Revascularization (coronary artery bypass graft surgery (CABG) or
percutaneous coronary intervention (PCI)) may be considered when medical therapy
appears to be insuﬃcient in patients with coronary artery abnormalities. The results
of the Asymptomatic Cardiac Ischemia Pilot (ACIP) study indicate that high-risk pa-
tients with asymptomatic ischemia and signiﬁcant coronary artery abnormalities, who
undergo revascularization with CABG or PCI, may have a better outcome compared
to those only receiving medical therapy.25
CABG is advised in case of left main stenosis or 3-vessel disease. Overall, the im-
provement in survival with CABG compared to drug treatment is 4.3 months at
10-year follow-up. The eﬀect on survival is larger when the a priori risk is higher.
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The poorer the left ventricular function the larger is the potential beneﬁt of surgery.
In patients with left main disease, the survival beneﬁt of CABG compared to med-
ical therapy is 19.3 months at 10-year follow-up. Therefore, the beneﬁt of surgery
over drug treatment for patients with signiﬁcant left main stenosis (>50 %) is lit-
tle argued.26 CABG has an expected 30-day mortality of <1 % when performed in
elective patients <65 years of age, who have no severe LV dysfunction or congestive
heart failure. Technical modiﬁcations of traditional CABG have been developed in
the last several years in an attempt to decrease the morbidity of the operation, either
by using limited incisions or by eliminating the use of cardiopulmonary bypass.26
PCI may be considered when a high likelihood of success and a low risk of morbidity
or mortality exists, e.g., non-diabetic patients with asymptomatic ischemia with one
or more signiﬁcant lesions in one or two coronary arteries. Little eﬀort has been
directed toward comparing medical therapy with PCI.27 PCI has low risks and a high
initial success rate. Re-stenosis decreases long-term clinical success, but studies with
improved technologies, e.g. drug eluting stents, are promising.28
The treatment of silent myocardial ischemia in absence of severe coronary abnorma-
lities is not studied extensively. They are all conducted in small groups of patients
with coronary abnormalities. The presence of extensive ischemia on dobutamine
stress SPECT imaging, whether silent or not, indicates an increased risk of cardio-
vascular events, and as with exercise testing, the threshold at which ischemia occurs
carries important prognostic information.29
As discussed previously, stress imaging seems to allow for improved risk stratiﬁca-
tion. With a lack of evidence on the best treatment, silent ischemia in the absence
of coronary abnormalities is mainly an indication for an increase of anti-ischemic and
risk factor modifying medication. In a study by Kuijpers et al. dobutamine stress MR
testing had high accuracy in assigning risk levels for future cardiovascular events.30
However, the patients in this study were all suspected of CAD and not cardiac asymp-
tomatic.
In conclusion, at present CABG or PCI may be considered as ﬁrst line therapy in
case of severe abnormalities in the coronary artery tree, even in asymptomatic pa-
tients with a high risk of cardiac events. In addition, silent myocardial ischemia has
been shown to increase CAD risk and evidence indicates that in certain groups of
these patients CABG or PCI treatment may reduce the risk. Alternatively, optimizing




In summary, symptomatic ECAD is a common disease associated with a consider-
able increased risk of future coronary events and with a high prevalence of coronary
atherosclerotic disease. Patients with aneurysmal or stenotic artery abnormalities
may have similar risks. Therefore, in this thesis it is studied whether coronary athero-
sclerosis in these patients has a similarly high prevalence. Improvement of the prog-
nosis of these patient groups is needed. Screening for CAD has become a realistic
possibility with recent developments in cCTA and MR stress testing. Non-invasive
cardiac imaging joined with a dedicated treatment algorithm based on the imaging
ﬁndings, may beneﬁcially aﬀect the prognosis patients with aneurysmal or stenotic
artery abnormalities, by reducing the incidence of cardiovascular events.
One of the weaknesses of cCTA has always been coronary calcium. A large amount
of calcium causes blooming artifacts, which hinder coronary lumen evaluation. How-
ever, CT has evolved enormously since its introduction, while calcium score cut-oﬀ
has remained the same. To assess whether diagnostic accuracy of cCTA for coronary
stenosis with modern CT scanners is adequate in patients with a high calcium score,
a meta-analysis is performed in Chapter 2.
To evaluate the necessity of cardiac imaging in cardiac asymptomatic patients at
high risk, a cohort of cardiac asymptomatic patients with known ECAD underwent
non-invasive imaging by cCTA and APMR. In Chapter 3, the results of this study
are reported and the prevalence of severe, asymptomatic CAD in these patients is
described.
Currently, no established non-invasive imaging modality can depict both anatomically
and functionally CAD in a single examination. In Chapter 4 a novel method to assess
hemodynamic signiﬁcance of stenoses based on common cCTA data is introduced,
the so-called corrected contrast opaciﬁcation evaluation.
cCTA yields additional information that may have diagnostic and prognostic value
beyond the evaluation of coronary stenosis. One such measure, the amount of epi-
cardial fat, is investigated in Chapter 5. Lastly, in Chapter 6 a novel non-invasive
skin-derived marker of inﬂammation and atherosclerosis is investigated in relation
with the degree of atherosclerosis on cCTA. Possibly, this new marker could aid in
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Objectives A systematic review and meta-analysis to assess sensitivity and speciﬁcity
of coronary CT angiography (cCTA) for signiﬁcant stenosis at diﬀerent degrees of
coronary calciﬁcation.
Methods A literature search was performed including studies describing test char-
acteristics of cCTA for signiﬁcant stenosis, performed with at least 16-MDCT and
according to calcium score (CS). Invasive coronary angiography was the reference
standard. Pooled sensitivity and speciﬁcity of cCTA by CS categories and CT equip-
ment were calculated.
Results Of 14,121 articles, 51 reported on the impact of calcium scoring on di-
agnostic performance of cCTA and could be included in the systematic review.
Twenty-seven of these studies (5,203 participants) were suitable for meta-analysis.
On patient-basis, sensitivity of cCTA for signiﬁcant stenosis was 95.8, 95.6, 97.6
and 99.0 % for CS 0-100, 101-400, 401-1,000 and >1,000, respectively. Speciﬁcity
was 91.2, 88.2, 50.6 and 84.0 %, respectively. Speciﬁcity of cCTA was signiﬁcantly
lower for CS 401-1,000 due to lack of patients without signiﬁcant stenosis. Sensitiv-
ity and speciﬁcity of 16-MDCT were signiﬁcantly lower compared to more modern
CT systems.
Conclusion Even in cases of severe coronary calciﬁcation, sensitivity and speciﬁcity
of cCTA for signiﬁcant stenosis are high. With 64-MDCT and newer CT systems, a
CS cut-oﬀ for performing cCTA no longer seems indicated.
Published in European Radiology




Computed tomography (CT) is increasingly used for non-invasive imaging of the
coronary arteries. With the rising number of detectors in multidetector CT (MDCT)
and the introduction of dual-source CT (DSCT), the accuracy of coronary CT an-
giography (cCTA) for detection of obstructive stenosis compared to invasive coronary
angiography has improved,1–3 with sensitivity increasing from 81 % for 16-MDCT to
94-100 % for newest CT systems at maintained high speciﬁcity of 92-95 %.4–6
The speciﬁcity of cCTA may be aﬀected by coronary calciﬁcation, since severe calci-
ﬁcation limits lumen assessment due to blooming artifacts.7 In case of a high calcium
score (CS), cCTA can yield false positive results, which is one of the main reasons
why current guidelines still consider a high CS a contra-indication for performing
cCTA.8,9 For this reason, some study groups have limited cCTA to patients with
CS below an arbitrary cut-oﬀ, with invasive coronary angiography being used for di-
agnostic purposes in those with higher CS.3,8,10–13 In other studies, no CS cut-oﬀ
was applied.1,2,4–7,14–51 The question arises, especially with the improved technology
of latest CT systems, whether a CS cut-oﬀ is needed to obtain good diagnostic
accuracy in cCTA.
We performed a systematic review and meta-analysis to: (1) review the CS cut-
oﬀ values reported in literature; (2) assess sensitivity and speciﬁcity of cCTA by
MDCT and DSCT for signiﬁcant stenosis (≥50 %) at diﬀerent degrees of coronary
calciﬁcation.
2.2 Materials and Methods
Data sources
Pubmed and Embase were searched for studies published between January 2001
and June 2011, using the following search terms: "Coronary Angiography"[MeSH]
OR "Coronary Artery Disease"[MeSH] OR "Coronary Stenosis"[MeSH] OR coro-
nary[TIAB]) AND "Tomography, X-Ray Computed"[MeSH] OR CT[TIAB] OR MD-
CT[TIAB] OR DSCT[TIAB] OR "computed tomography"[TIAB] (Limits: Publi-
cation Date from 2001/1/1). We combined MeSH terms with free text searches
to assure the maximum number of suitable articles. In Embase the same search
was performed, but MeSH terms were translated into Emtree terms. As a starting
date, 2001, the year 16-MDCT was introduced, was chosen as 16-MDCT is still
frequently used for cCTA48 and minimum recommended for calcium scoring.52 The
meta-analysis was executed and reported according to the Meta-Analysis of Obser-
vational Studies in Epidemiology (MOOSE)53 and the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA) statements.54
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Study selection
Two reviewers independently assessed articles for suitability. Disagreements were
resolved by a third reviewer. The articles were ﬁrst screened on title and abstract.
When considered suitable or when in doubt, the full text was reviewed. Reference
lists of suitable articles were searched for additional studies. Studies were included
in the systematic review if they: (1) used or suggested a CS cut-oﬀ for performing
cCTA; or (2) addressed diagnostic accuracy of cCTA according to CS categories.
Articles were excluded if they: (1) were laboratory or phantom studies; (2) concerned
a review or case report; (3) included examinations of stented or bypassed coronary
arteries; or (4) used <16-MDCT. There was no language restriction for the search,
but during selection language was restricted to English. Articles in the systematic
review were subsequently included in the meta-analysis if they: (1) reported test
characteristics of cCTA by CS categories; (2) used invasive coronary angiography as
reference standard; and (3) reported patient characteristics.
Data extraction
Using a standardized form, two reviewers extracted author, year of publication, study
design, type and brand of CT system, study population size, mean or median patient
age, body mass index, heart rate during CT data acquisition, use of beta-blockers
or nitro-glycerine during CT data acquisition, mean or median CS with range, num-
ber of examined segments and non-interpretive or excluded segments with reasons,
sensitivity, speciﬁcity, positive and negative predictive value (PPV and NPV), and if
available, accuracy (total and per CS) per patient and per segment. A third reviewer
veriﬁed the assembled data in case of discrepancies.
Quality assessment
Methodological quality and potential sources of bias in the meta-analysis articles were
assessed with 14 standard items of the Quality Assessment of Diagnostic Accuracy
Studies (QUADAS) tool.54,55 For each article, a quality score was accumulated by
assigning 1 point to each QUADAS item that was fulﬁlled, 0.5 point to unclear items,
and 0 points to un-fulﬁlled items. A score ≥11 points was considered high-quality
and a score <11 points was considered low-quality.56 Patient spectrum was deﬁned
as patients at intermediate risk of coronary artery disease or primarily referred for
cCTA. Time period between tests was deﬁned as 1 month. Two reviewers evaluated
independently, with disagreements resolved by the third reviewer.
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Statistical analysis
For the systematic review we summarized the data. For the meta-analysis, studies
were divided in categories based on whether they reported the results per segment or
per patient (or both). We predeﬁned CS categories of 0-100, 101-400, 401-1,000
and >1,000. Study results were matched to these categories. If CS categories in the
studies did not match predeﬁned categories, we compared median CS with 25th/75th
percentile of the reported categories to the predeﬁned categories. If median CS was
not available, we used mean CS with standard deviation. The results of reported
categories were then included in the predeﬁned category in which 80 % of the pa-
tients fell. In a subsequent analysis the studies were stratiﬁed by CT system type.
Sensitivity, speciﬁcity, PPV, NPV, positive and negative likelihood ratios, and diag-
nostic odds ratio were calculated from the true positive, false positive, false negative
and true negative. If counts were unavailable, we calculated these from available di-
agnostic test characteristics using an internet tool.57 From reconstructed data, test
characteristics were back-calculated for veriﬁcation. We used a two-level mixed logis-
tic regression model, taking into account random eﬀects. For all calculations, 95 %
conﬁdence intervals (CIs) were obtained using the F distribution method to compute
the exact conﬁdence limits for the binomial proportion. The sensitivity and speciﬁcity
per CS category were pooled weighted to the study sample size. A forest plot was
generated to visualize this information. A summary receiver operating characteris-
tics (sROC) curve was constructed to assess the diagnostic performance.58 Analyses
were repeated after exclusion of low-quality studies and after exclusion of studies
that excluded over 10 % of segments. The normality of data on non-assessable and
false positive segments was tested with the Kolmogorov-Smirnov test. The diﬀer-
ence between 16-MDCT and newer CT systems regarding non-assessable and false
positive segments was then compared with a weighted Mann-Whitney U test.
Publication bias was assessed with the Begg and Mazumdar rank correlation and
Egger’s regression test. Heterogeneity and inconsistency was tested with the Cochran
Q test and I2 statistic for sensitivity and speciﬁcity separately.59,60 Possible sources
of heterogeneity were predeﬁned and checked in subgroup analyses based on CS,
average age, gender, CT system employed, study size, study design, slice thickness,
tube current, and iodine contrast.61,62 Statistical analyses were performed using Stata
SE 11.2 (StataCorp, College Station, USA), METANDI package63 and Meta-DiSc,
version 1.4 (Hospital Universitario Ramón y Cajal, Madrid, Spain).
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2.3 Results
Systematic review
The results of the literature search including reasons for exclusion of articles are
shown in Figure 2.1. In the primary search, 14,121 articles were retrieved. On
the basis of title and abstract, 13,784 articles could be excluded. After reviewing
437 full-text articles, 51 were included in the systematic review. Of these, 32 were
performed in Europe, 10 in Asia, 7 in the United States and 2 in Australia and Brazil.
The number of included patients ranged from 19 to 1,500. Overall mean patient age
was 60.7 years (range 48-70.8 years). Percentage men ranged from 42.4 to 87.5 %.
Mean CS varied from 96 to 1,589 and median CS from 15 to 1,146.
Twelve studies demonstrated good diagnostic accuracy of cCTA, even in case of high
CS. Of these, 16-MDCT was used in three studies,16–18 64-MDCT in four,14,19–21
DSCT in two,22,23 320-MDCT in one.64 The last compared 64-MDCT to DSCT.24
Thirty-four studies suggested a cut-oﬀ. The recommendations of 24 studies were
based on the decrease in diagnostic accuracy of cCTA and the risk of non-diagnostic
examinations,2–6,8,10,12,15,24–38 6 were based on the probability of coronary artery
disease (CAD)39–44 and 3 on the ROC.45–47 Of the 34 studies, 7 suggested a CS
cut-oﬀ of around 100 (range 40-142). Three suggested a cut-oﬀ of about 300 (range
297-350), 16 suggested a cut-oﬀ of 400. Eight studies opted for a cut-oﬀ of >400:
one for 600, one for 800 and six for 1,000. The suggested CS cut-oﬀ diﬀerect by CT
system type. Five studies found a decrease in accuracy or quality of cCTA, without
proposing a CS cut-oﬀ.7,48–51
Seven studies applied a CS cut-oﬀ above which no cCTA was performed. Mentioned
CS cut-oﬀs were 400,13 500,11 600,3 800,12 and 1,000.8,10 One study64 applied a
minimum CS cut-oﬀ of 600.
Meta-analysis: study and patient characteristics
Twenty-seven studies were included in the meta-analysis. In total, 5,203 patients
were included. Characteristics per study are presented in Table 2.1. On average, 193
patients were included per study (range 30-1,500). The mean CS was 500 Agatston
Units (range 0-8,420), median 220 (interquartile range 133-330). The median age
was 62 years (interquartile range 59-63) and 67 % were male. Of included patients,
767 (14.7 %) had diabetes, 2,372 (45.6 %) hypertension, 2,617 (50.3 %) hyperlipi-
demia and 906 (17.4 %) obesity. Smoking was present in 1,658 (31.9 %) patients.
One hundred and seventy-six (3.4 %) patients were asymptomatic, 680 (13.1 %) had
atypical chest pain, 1,866 (35.9 %) had typical angina, 769 (14.8 %) had unstable
angina or non-ST-wave myocardial infarction and 1,406 (27.0 %) were suspected of
CAD for other reasons. CT was performed preoperatively in 306 (5.9 %) patients.
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Figure 2.1: Flow chart of the literature search
20,410 potentially relevant
           articles
       Pubmed 9,959     
       Embase 10,445
       References 6
6,289 duplications
14,121 articles screened
based on title and abstract
13,784 excluded:
  Foreign language,
  non-human studies,
  not relevant
437 articles retrieved and
screened based on full text
386 excluded:
  No calcium score,
  no quality assessed,
  review article,
  less than 16-MDCT,
  duplicate data
51 articles included
41 assessed diagnostic performance
10 used CS cutoff
27 articles (5,203 patients) included 
in meta-analysis
On invasive coronary angiography, 2,075 patients (39.4 %) had at least one stenosis
with ≥50 % lumen diameter reduction, with signiﬁcant CAD in one, two and three
vessels in 15, 10 and 5 % of patients, respectively. Furthermore, 1.5 % of patients
had non-quantiﬁed multivessel disease and 8 % of patients had signiﬁcant CAD,
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single- or multivessel. On CT, signiﬁcant stenosis was present in 36.8 % of patients
with CS 0-100, 58.4 % with CS 101-400, 86.2 % with CS 401-1,000 and 67.1 %
with CS >1,000. Twenty-one studies with a total of 4,504 patients reported patient-
based results, and 23 studies with a total of 56,256 segments showed segment-based
results. In these studies, an extra 1,539 segments were excluded. In most studies,
the main reasons were motion artifacts or small vessel size. Only ﬁve studies specif-
ically mentioned the exclusion of segments due to severe calciﬁcation.4,26,28,29,40
In patient-based (segment-based) analyses, 3 (6) studies used 16-MDCT, 12 (9)
64-MDCT, 1 (1) 320-MDCT and 5 (7) DSCT.
Meta-analysis: study quality
Quality assessment is shown in Figure 2.2. Overall, the quality of included articles was
high (mean score, 11.8; 3 studies with score <11). Many studies were performed
double-blinded, so they fulﬁlled the clinical review bias item (clinical review bias
avoided). In 96 % of the studies, interpreters of cCTA were blinded to the results
of invasive coronary angiography (test review bias avoided) and vice versa in 74 %
(diagnostic review bias avoided).
Figure 2.2: Study quality summaries of articles included in the meta-analysis, assessed by the
Quality Assessment of Diagnostic Accuracy Studies (QUADAS) tool
Diagnosti review bias avoided




Selection criteria clearly described
Reference standard likely to classify CAD
Time period between tests short enough
Partial verification bias avoided
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Incorporation bias avoided
Index test clearly described
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Table 2.1: Characteristics of the 27 studies included in the meta-analysis













Maﬀei14 2011 64-MDCT 1,500 58± 12 928/572 0, 1-10, 11-100, 101-400,
401-1,000, >1,000
0
Gang6 2011 320-MDCT 60 68± 9 38/22 0-100, >100 0
Nazeri31 2011 64-MDCT 168 58± 11 126/42 0-100, 101-418, 419-8,420 0
Zhang5 2010 DSCT 113 64± 12 82/13 0-100, 101-400, >400 11 (0.7)
Dewey51 2010 64-MDCT 291 59.3± 10 214/77 0-100, 101-300, 301-600 na
Bettencourt32 2009 64-MDCT 237 67± 10 114/123 ≤10, 11-400, 401-1,000,
>1,000
167 (4.1)
Meijs24 2009 64-MDCT 360 60± 6 245/115 <10, 10-99, 100-399,
≥400
na
Meng37 2009 DSCT 109 63± 9 68/41 0-100, 101-400, >400 25 (1.6)
Palumbo39 2009 64-MDCT 200 57± 13 169/31 0, 1-10, 11-100, 101-400,
>400
0
Diederichsen25 2009 64-MDCT 109 63± 11 58/51 0 vs. >0, ≤50 vs. >50,
≤100 vs. >100, ≤200 vs.
>200, ≤400 vs. >400
na
Marano48 2009 16-, 64-MDCT 350 64 265/85 0-100, 101-400,
401-1,000, >1,000
0
Stolzmann22 2008 DSCT 100 64.2± 6.5 62/38 0-315, ≥316 76 (4.8)
Budoﬀ33 2008 64-MDCT 230 57± 10 136/94 0-400, >400 na
Ulimoen26 2008 64-MDCT 48 65.1 31/29 0-300, >300 177 (26.6)
Brodoefel34 2008 DSCT 100 62± 10 80/20 0-100, 101-400, >400 71 (5.5)












































Table 1.1 : continued













Brodoefel35 2007 64-MDCT 102 62± 10 82/20 0-100, 101-400, >400 26 (2.0)
Hausleiter2 2007 16-, 64-MDCT 243 62.0± 9.9 158/85 0-999, ≥1,000 0
Meijboom50 2007 64-MDCT 104 59 75/29 0-105, 107-375, 400-2,870 181 (10.6)
Coles28 2007 16-MDCT 120 61.9± 10.7 78/42 <100, 100-400, >400 273 (22.0)
Burgstahler15 2007 DSCT 41 66.2± 8.4 35/6 0-350, >350 0
Scheﬀel23 2006 DSCT 30 63.1± 11.3 24/6 <400, ≥400 46 (9.9)
Mitsutake40 2006 16-MDCT 92 63± 11 68/24 0, 1-399, ≥400 101 (11.0)
Manghat4 2006 16-MDCT 40 70.8± 10 27/13 ≤400 vs. >400, ≤1,000
vs. >1,000
38 (8.4)
Ong29 2006 64-MDCT 134 54.5± 8.8 98/36 <142, ≥142 143 (9.7)
Mollet20 2005 64-MDCT 52 59.6± 12.1 34/18 0-10, 11-400, 401-1,000,
>1,000
142 (16.4)
Cademartiri18 2005 16-MDCT 120 59± 11 105/15 <55, ≥55 0
CT Computed tomography, SD standard deviation, MDCT multidetector computed tomography, DSCT dual-source computed tomogra-




Publication bias was present in neither patient-based nor segment-based analysis.
The overall pooled sensitivity and speciﬁcity were 96.9 % (95 % CI, 96.1-97.5) and
86.4 % (95 % CI, 84.9-87.9) in patient-based analyses. On a per-segment basis
the pooled results were 88.8 % (95 % CI, 88.0-89.5) and 94.9 % (95 % CI, 94.7-
95.1), respectively. Sensitivity and speciﬁcity by CS categories can be found in Table
2.2. Compared to the overall pooled speciﬁcity, a CS of 0-100 scored signiﬁcantly
better (P <0.01). In patient-based analyses, the speciﬁcity for CS of 401-1,000
was signiﬁcantly lower than overall (P <0.01). The speciﬁcity for CS over 1,000
was 84.0 % (95 % CI, 76.5-89.9), not signiﬁcantly diﬀerent from the overall pooled
speciﬁcity. The drop in speciﬁcity for CS of 401-1,000 was not seen in segment-
based analyses. In segment-based analyses, the speciﬁcity decreased signiﬁcantly
with increasing calcium score, from 98.4 % for CS 0-100 to 88.6 % for CS over
1,000 (P <0.01). Exclusion of low-quality studies did not alter the results.
Table 2.2: Characteristics of the 27 studies included in the meta-analysis
Calcium score Sensitivity (95 % CI) Speciﬁcity (95 % CI)
Per Patient Overall 96.9 (96.1-97.5) 86.4 (84.9-87.9)
Calcium score 0-100 95.8 (93.8-97.2) 91.2 (89.3-92.9)⋆
100-400 95.6 (93.7-97.1) 88.2 (84.8-91.0)
400-1,000 97.6 (95.9-98.7) 50.6 (39.5-61.7)⋆
>1,000 99.0 (97.0-99.8) 84.0 (76.5-89.9)
Per Segment Overall 88.8 (88.0-89.5) 94.9 (94.7-95.1)
Calcium score 0-100 93.0 (91.5-94.3)⋆ 98.4 (98.2-98.6)⋆
100-400 90.4 (88.8-91.8) 94.6 (94.2-94.9)
400-1,000 89.8 (88.1-91.3) 90.9 (90.1-91.7)⋆
>1,000 94.9 (93.5-96.1)⋆ 88.6 (87.7-89.5)⋆
CI Conﬁdence interval ⋆ P <0.05 in comparison to overall test characteristic
SROC curves on patient-basis are shown in Figure 2.3. Area under the curve for the
ROCs was 0.97 (95 % CI, 0.96-0.99), 0.97 (95 % CI, 0.94-1.00), 0.87 (95 % CI,
0.74-1.00) and 1.00 (95 % CI, 0.97-1.00) for increasing CS categories in patient-
based analysis. On a per-segment basis it was 0.99 (95 % CI, 0.97-1.00), 0.98
(95 % CI, 0.96-0.99), 0.97 (95 % CI, 0.94-0.98) and 0.98 (95 % CI, 0.96-1.00),
respectively.
16-MDCT had a signiﬁcantly lower speciﬁcity in patient- and segment-based analyses
(P <0.01), as well as a lower sensitivity on a per-segment basis (P <0.01). 64-
MDCT and newer CT systems had signiﬁcantly improved sensitivity and speciﬁcity
(P <0.05). Results can be found in Table 2.3.
In 16-MDCT, 3 of 6 studies reported exclusion of segments due to heavy calciﬁcation,
while only 2 of 17 studies using 64-MDCT or newer CT systems reported this.
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The median percentage of non-assessable segments was considerably higher in 16-
MDCT than in 64-MDCT and newer CT systems: 6.1 (interquartile range 3.6-6.1)
versus 0.0 (interquartile range 0.0-0.7), respectively (P <0.001). Even so, the mean
percentage of false positive results of stenosis on cCTA was signiﬁcantly higher in 16-
MDCT than in 64-MDCT and newer CT systems, 9.0 (interquartile range 4.2-9.0)
versus 4.3 (interquartile range 3.3-4.3) (P <0.001). The number of false positive
results in case of CS >400 was minimally higher in 16-MDCT compared to 64-MDCT
and newer CT systems, 3.1 (interquartile range 2.5-3.7) versus 2.5 (interquartile
range 2.0-2.5) (P <0.001).
Meta-analysis: subgroup analysis
Patient- and segment-based analyses showed heterogeneity (I2 of 86 and 96 %
respectively). To assess possible sources of heterogeneity, we performed several
subgroup analyses. Results for subgroups in patient-based analyses are shown in
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Table 2.3: Sensitivity and speciﬁcity of coronary CT angiography by scanner generation
Subgroup Number of patients
(studies)
Sensitivity (95 % CI) Speciﬁcity (95 % CI)
Per Patient Overall 96.9 (96.1-97.5) 86.4 (84.9-87.9)
Scannertype
16-MDCT 626 (3) 95.0 (92.1-97.0) 77.6 (72.2-82.3)⋆
64-MDCT 3,366 (12) 97.2 (96.3-97.9) 87.5 (85.8-89.1)
320-MDCT 60 (1) 100 (92.3-100) 92.9 (66.1-99.8)
DSCT 502 (5) 96.6 (93.9-98.4) 89.8 (84.8-93.6)
Per Segment Overall 88.8 (88.0-89.5) 94.9 (94.7-95.1)
Scannertype
16-MDCT 10,791 (6) 75.4 (73.1-77.6)⋆ 92.4 (91.9-93.0)⋆
64-MDCT 35,074 (9) 92.9 (92.0-93.8)⋆ 95.4 (95.2-95.7)⋆
320-MDCT 866 (1) 95.3 (91.0-98.0)⋆ 97.6 (96.1-98.6)⋆
DSCT 9,525 (7) 92.0 (90.5-93.4)⋆ 95.5 (95.0-95.9)
CI Conﬁdence interval MDCT multidetector computed tomography DSCT dual-source
computed tomography ⋆ P <0.05 in comparison to overall test characteristic
Table 2.4. Compared to overall pooled results, signiﬁcantly lower sensitivity and
speciﬁcity were found for multicenter trials (P <0.05). Signiﬁcantly higher speci-
ﬁcity was found for studies with consecutive inclusion of patients (P <0.05), and for
studies using thinner CT slice thickness (P <0.01).
Subgroup results for segment-based analyses are shown in Table 2.5. Most results
were similar to the patient-based analyses. Signiﬁcantly lower speciﬁcity was found
for studies with non-consecutive inclusion (P <0.01), studies with more women
(P <0.01), thicker slice thickness (P <0.01), higher current (P <0.05) and higher
iodine concentration (P <0.01). The lower speciﬁcity associated with high iodine
contrast material and higher tube current can be explained by the number of 16-
MDCT studies and the 16-MDCT study of Coles et al,28 respectively.
Exclusion of studies that excluded over 10 % of segments did not inﬂuence diagnostic
performance.
2.4 Discussion
This meta-analysis in 5,203 patients shows that speciﬁcity of cCTA for signiﬁcant
stenosis remained high in case of severe coronary calciﬁcation, with newer CT systems
of 64-MDCT and beyond. For patients with CS over 1,000, the speciﬁcity of cCTA
was 84 % (89 % in segment-based analysis), not signiﬁcantly lower than overall. The
test characteristics for 16-MDCT were signiﬁcantly worse. The results suggest that
for modern CT systems (at least 64-MDCT), a high CS should not necessarily imply
cancellation of cCTA.
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Table 2.4: Patient-based sensitivity and speciﬁcity of coronary CT angiography by subgroups
Subgroup Number of
patients (studies)
Sensitivity (95 % CI) Speciﬁcity (95 % CI)
Age
Average ≤62 3,024 (9) 97.2 (96.3-97.9) 86.5 (84.5-88.3)
Average >62 1,530 (12) 96.1 (94.4-97.4) 86.4 (83.7-88.7)
Gender
Males ≤70 % 3,329 (13) 98.1 (97.3-98.7) 86.0 (84.2-87.7)
Males >70 % 1,225 (8) 94.3 (92.5-95.8)⋆ 88.1 (84.6-91.1)
Study size
≤120 Patients 736 (9) 97.5 (95.6-98.7) 90.5 (85.9-94.0)
>120 Patients 3,818 (12) 96.7 (95.8-97.5) 85.9 (84.3-87.5)
Study design
Consecutive 2,479 (8) 98.1 (97.2-98.7) 90.0 (88.1-91.7)⋆
Non-consecutive 1,200 (5) 97.8 (96.1-98.9) 82.1 (77.6-86.1)
Multicenter 875 (8) 93.7 (91.6-95.5)⋆ 81.4 (77.9-84.6)⋆
Slice thickness
Slice <0.75 mm 2,489 (8) 96.7 (95.6-97.5) 91.0 (89.2-92.6)⋆
Slice ≥0.75 mm 722 (6) 96.0 (93.9-97.6) 83.1 (77.7-87.7)
Tube current
Current <500 mAs 1,221 (8) 94.3 (92.3-95.9)⋆ 87.3 (84.2-90.0)
Current ≥500 mAs 2,984 (10) 98.4 (97.6-98.9)⋆ 85.9 (83.9-87.7)
Contrast
Iodine <350 mg/ml 877 (7) 97.2 (95.2-98.5) 84.9 (81.0-88.2)
Iodine ≥350 mg/ml 2,147 (12) 95.5 (94.2-96.6) 82.6 (79.9-85.0)
CI Conﬁdence interval ⋆ P <0.05 in comparison to overall test characteristic
In a recent meta-analysis on this topic that only included 64-MDCT studies, Abdulla
et al.65 concluded that cCTA was not feasible for CS over 400, with a speciﬁcity
of 85 % and 66.5 % for low and high CS. However, other studies have shown the
quality of DSCT has signiﬁcantly improved compared to MDCT.32,58 This was the
reason for the current meta-analysis, and for including diﬀerent CT systems that
are deemed accurate for evaluating CS (16-MDCT and beyond). Additionally, we
analyzed categories that included higher CS levels than previously, and in subgroups,
to evaluate the impact of diﬀerent factors on the test characteristics. Similar to
the study by Abdulla,65 we found a signiﬁcant reduction in patient-based speciﬁcity
for CS between 401 and 1,000. The reason for this ﬁnding is that in this speciﬁc
group, the contributing studies reported few to no patients without signiﬁcant steno-
sis on invasive coronary angiography. For a CS over 1,000, the speciﬁcity was not
signiﬁcantly diﬀerent from the overall speciﬁcity. Interestingly, of patients with a CS
over 1,000, a larger proportion did not have signiﬁcant stenosis on invasive coronary
angiography. We suspect selection bias of patients is a contributing factor.
In the meta-analysis the speciﬁcity of 16-MDCT was signiﬁcantly lower both in
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Sensitivity (95 % CI) Speciﬁcity (95 % CI)
Age
Average ≤62 36,885 (11) 90.8 (89.8-91.6)⋆ 94.5 (94.2-94.7)
Average >62 19,371 (12) 85.0 (83.5-86.5)⋆ 95.7 (95.4-96.0)⋆
Gender
Males ≤70 % 15,029 (10) 90.1 (88.5-91.5) 93.6 (93.1-94.0)⋆
Males >70 % 41,227 (13) 88.4 (87.4-89.3) 95.4 (95.2-95.6)⋆
Study size
≤120 Patients 13,601 (13) 90.8 (89.4-92.0) 94.7 (94.3-95.1)
>120 Patients 42,655 (10) 87.9 (86.9-88.8) 95.0 (94.7-95.2)
Study design
Consecutive 39,661 (13) 91.8 (90.9-92.6)⋆ 95.6 (95.4-95.8)⋆
Non-consecutive 11,967 (9) 88.3 (86.8-89.8) 92.1 (91.5-92.6)⋆
Multicenter 4,628 (1) 70.5 (66.7-74.1)⋆ 95.8 (95.4-96.2)⋆
Slice thickness
Slice <0.75 mm 33,362 (8) 90.1 (89.1-91.1) 95.8 (95.6-96.0)⋆
Slice≥0.75 mm 11,673 (9) 84.8 (83.0-86.4)⋆ 93.7 (93.2-94.2)⋆
Tube current
Current <500 mAs 13,881 (10) 90.6 (89.2-91.8) 96.1 (95.8-96.5)⋆
Current ≥500 mAs 37,327 (11) 90.7 (89.7-91.6)⋆ 94.3 (94.1-94.6)⋆
Contrast
Iodine <350 mg/ml 10,238 (7) 92.1 (90.7-93.4)⋆ 96.1 (95.6-96.5)⋆
Iodine ≥350 mg/ml 23,737 (13) 83.8 (82.4-85.1)⋆ 94.1 (93.8-94.4)⋆
CI Conﬁdence interval ⋆ P <0.05 in comparison to overall test characteristic
patient-based and segment-based analysis. In patient-based analyses, there was no
signiﬁcant diﬀerence between newer CT systems and overall. In segment-based anal-
yses, both sensitivity and speciﬁcity for 64-MDCT and newer CT systems were signi-
ﬁcantly better. Even in case of severe calciﬁcation there was no signiﬁcant diﬀerence
in sensitivity or speciﬁcity compared to overall test characteristics. The systematic
review showed that there is a broad diversity in CS cut-oﬀs proposed, although a cut-
oﬀ of 400 was most commonly used. Interestingly, despite the increasing accuracy,
there was a tendency for recommending lower CS cut-oﬀs for newer CT systems. The
current meta-analysis shows that accuracy of cCTA has considerably improved with
64-MDCT and newer CT systems, implicating that chosen CS cut-oﬀs may not apply
to newer CT systems. This is in discordance with the latest appropriate use criteria
report, which still qualiﬁes performing cCTA in case of a CS of 401-1,000 and over
1,000 as uncertain, under the assumption of 64-MDCT as a minimum requirement.9
In that report, the use of cCTA was deemed appropriate in patients with a low and
intermediate pre-test probability of coronary artery disease, either symptomatic or
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pre-operative, similar to the patient populations included in this meta-analysis.
Some studies in the meta-analysis also included patients with high pre-test probability
of CAD. A large percentage of these patients were present in the category of a
calcium score between 401 and 1,000. In total 3 of 11 studies included patients
with a high pre-test probability. This may partly explain the high prevalence of
signiﬁcant coronary artery disease in this patient group. According to the appropriate
use criteria9 there is no indication for cCTA in a high risk population. On the other
hand, in the patient group with a calcium score over 1,000, more patients were at
low and intermediate pre-test probability. In this group, as many as one-third of
patients did not have signiﬁcant stenosis. We focused on the diagnostic accuracy
of cCTA for stenosis detection according to the CS. Thus, this study did not set
out to answer the question whether in patients with high probability of signiﬁcant
CAD invasive coronary angiography rather than cCTA is indicated in case of a high
CS, based on a high overall prevalence of signiﬁcant stenosis. Also, according to
the current guidelines, there is no indication for cCTA in asymptomatic patients with
high calcium scores.
Even though diagnostic accuracy of cCTA is high with modern CT technology, and
a CS cut-oﬀ may no longer be necessary, there are issues to keep in mind. If the
CS is based on considerable calciﬁcation limited to a small area, there is a greater
probability of artefacts and false positive results of cCTA, compared to a more even
distribution of coronary calciﬁcation. Considering this, cCTA can be non-diagnostic
for a certain coronary segment in case of a CS of 100, while CCTA in a patient
with a CS of 1,500 can have good diagnostic quality;7,66 Coles28 found a decrease
in accuracy for proximal segments mainly due to quantity of calcium. Cademartiri18
and Mollet20 found that large calcium deposits led to overestimation of lesion grade,
but cCTA still maintained high overall sensitivity and speciﬁcity. With modern CT
systems, the percentage of non-assessable segments has signiﬁcantly decreased, in
this meta-analysis from 5.8 % in 16-MDCT to 1.4 % in 64-MDCT and newer CT
systems, while the mean number of false positive segments has also decreased with
64-MDCT and newer CT systems. Despite the fact that more segments were ana-
lyzed, likely also including more segments with considerable calciﬁcation, the percent-
age of false positive segments for a CS >400 in 64-MDCT and newer CT systems
showed a minimal decrease from 3.1 to 2.5 %. The studies that reported excluding
some segments due to heavy calciﬁcation did not specify what the calcium score of
the speciﬁc segments or of the involved patients were. However, the studies did not
exclude all segments of a patient, even in case the patient had a total calcium score
over 1,000.
In clinical practice, the decision whether or not to perform cCTA, if dependent on
CS, is usually based on the total CS and not on the distribution of calciﬁed lesions.
In this study we could not take calcium distribution into account when investigating
the performance of cCTA.
Limitations to the current study include the fact that arbitrary cut-oﬀs were chosen
28
2.4 Discussion
for the CS categories. However, CS cut-oﬀs were based on values commonly reported
in literature. Also, as CS categorisation for individual studies sometimes had to be
ﬁtted to the predeﬁned categories, there could be partial overlap of CS ranges for
ﬁtted study categories with neighbouring CS categories. As this was randomly the
case, we do not expect this to have caused a systematic bias, although it could
have slightly attenuated diﬀerences in test characteristics between CS categories.
Furthermore, we restricted the systematic review to studies that reported the CS
or a CS cut-oﬀ in association with cCTA. In many articles on cCTA, the CS is not
mentioned. These studies may have performed cCTA even in high CS. The results
of these studies could not be included in the systematic review or the meta-analysis.
Second, there are limited cCTA publications on 256- or 320-MDCT; thus we could
not accurately evaluate the performance of these modern MDCT machines.
In conclusion, with 64-MDCT and newer CT systems, the sensitivity and speciﬁcity
of cCTA for signiﬁcant stenosis remain high in case of severe coronary calciﬁcation.
Therefore a CS cut-oﬀ above which cCTA should not be performed seems no longer
to be indicated.
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coronary artery disease on cardiac CT
and MRI in patients with extra-cardiac
arterial disease
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Objectives Patients with extra-cardiac arterial disease (ECAD) are at high risk of
coronary artery disease (CAD). Prevalence of silent, signiﬁcant CAD in patients with
stenotic or aneurysmal ECAD was examined. Early detection and treatment may
reduce CAD mortality in this high-risk group.
Methods ECAD patients without cardiac complaints underwent computed tomo-
graphy (CT) for calcium scoring, coronary CT angiography (cCTA), if calcium score
≤1,000, and adenosine perfusion magnetic resonance imaging (APMR) if no left
main stenosis. Signiﬁcant CAD was deﬁned as calcium score >1,000, cCTA-detected
coronary stenosis of ≥50 % lumen diameter, and/or APMR-detected inducible myo-
cardial ischemia. In case of left main stenosis (or equivalent) or myocardial ischemia,
patients were referred to a cardiologist.
Results The prevalence of signiﬁcant CAD was 56.8 % (95 % conﬁdence inter-
val 47.5-66.0 %) One-hundred-eleven patients were included. Eighty-four patients
(76 %) had stenotic ECAD, and 27 (24 %) had aneurysmal disease. In patients
with stenotic ECAD, signiﬁcant coronary stenosis was present in 32 (38 %), in-
ducible ischemia in 8 (12 %). Corresponding results in aneurysmal ECAD were 8 (30
%) and 2 (11 %), respectively (P for diﬀerence >0.05). Sixteen (19 %) patients
with stenotic and 6 (22 %) with aneurysmal ECAD were referred to a cardiologist,
with subsequent cardiac intervention in 7 (44 %) and 3 (50 %), respectively (both
P >0.05).
Conclusion Patients with stenotic or aneurysmal ECAD have a high prevalence of
silent, signiﬁcant CAD.
Published in European Journal of Vascular and Endovascular Surgery




Extra-cardiac arterial disease (ECAD) is common in the Western population, with a
prevalence of 29 % in persons over 50 years.1 ECAD can be divided in stenotic and
aneurysmal disease. In ECAD patients, coronary artery disease (CAD) is the major
cause of death.2–4 Compared with individuals without ECAD, patients with ECAD
have over 5 times increased mortality risk, with an annual mortality rate >3 %, mostly
due to coronary heart disease.5 In patients undergoing vascular surgery, cardiac death
accounts for 45 to 67 % of the operative mortality (3.9 %).6 In view of the high
cardiac mortality in ECAD patients, early detection and evidence-based treatment of
silent, severe CAD could potentially improve prognosis.
Previous studies have shown that coronary revascularization can reduce the mortality
risk in case of signiﬁcant CAD, even in patients without cardiac complaints. The
Coronary Artery Surgery Study showed an increased survival rate from 57 to 88 %
for coronary artery bypass graft surgery (CABG) compared with medical manage-
ment in patients with silent severe CAD.7 In the Asymptomatic Cardiac Ischemia
Pilot study, the 2-year mortality in patients with silent signiﬁcant CAD was 1.1 % for
coronary revascularization compared with 6.6 % in case of conservative treatment.8
More recently, the CONFIRM registry (Coronary CT Angiography EvaluatioN For
Clinical Outcomes: An InteRnational Multicenter Registry) conﬁrmed a 2-year mor-
tality reduction for coronary revascularization compared with conservative treatment
(5.3 to 2.3 %) in patients with silent severe CAD.9
In case of severe CAD with or without symptoms, invasive treatment with percuta-
neous coronary intervention (PCI) or CABG is recommended.10,11 This is considered
particularly appropriate in patients at high risk (annual mortality risk >3 %),11 inclu-
ding ECAD patients. In ECAD, the survival beneﬁt of coronary revascularization ther-
apy has mainly been investigated in patients scheduled for elective vascular surgery. A
study in 1,000 patients with invasive coronary angiography reported improved 5-year
survival if CABG for silent severe CAD was performed prior to major vascular surgery
(survival 86-92 % for patients with CABG, compared with 62-69 % in those with
indication for CABG, but who did not undergo surgery).6 In a recent randomized
trial in patients undergoing carotid endarteriectomy, half of the 426 patients were
screened preoperatively by invasive coronary angiography.12 Silent severe CAD was
detected and revascularized in 31 %. In the screened group, no patient (0 %) died
in the 30 days postoperatively, versus 2 (4.2 %) in the non-screened group. A ran-
domized trial with 208 patients admitted for elective major vascular surgery showed a
higher 4-year coronary event-free survival in high-risk patients undergoing preopera-
tive coronary angiography and revascularization, compared with those without (86.6
vs 69.6 %, respectively).13
The exact prevalence of silent coronary stenosis and myocardial ischemia in the overall
population of patients with stenotic or aneurysmal ECAD is unknown. As coronary
angiography is an invasive procedure with some risk of morbidity and mortality, this
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procedure is generally only performed in case of strong suspicion of CAD.
With new imaging modalities, CAD can be detected non-invasively. Computed to-
mography (CT) without contrast agent depicts the amount of coronary calcium, ex-
pressed as a calcium score. Contrast-enhanced coronary CT angiography (cCTA) can
detect coronary luminal narrowing with high diagnostic accuracy,14 while adenosine
perfusion magnetic resonance imaging (APMR) can evaluate the functional signiﬁ-
cance of coronary stenosis on the myocardium under stress. APMR is more sensitive
than nuclear single-photon emission CT for detecting myocardial ischemia, with the
additional advantage of lack of radiation.15–17 Non-invasive detection and subsequent
treatment of silent severe CAD could lower CAD mortality in ECAD patients in the
future.
This study was performed to assess the prevalence of silent CAD in cardiac asymp-
tomatic patients with stenotic and aneurysmal ECAD using non-invasive imaging
techniques.
3.2 Materials and Methods
Patients
The GROUND2 study is a prospective multicenter study.18 Patients were recruited
from departments of vascular surgery at the University Medical Center Groningen
and Deventer Hospital. Patients were eligible if aged 50 years or older and diag-
nosed with symptomatic ECAD (peripheral artery obstructive disease [PAOD], carotid
artery stenosis or aortic aneurysm) by a vascular surgeon. PAOD was deﬁned by an
ankle-brachial index of ≤0.7 or previous surgical treatment. Carotid artery disease
was deﬁned as a stenosis of at least 50 % lumen diameter stenosis as diagnosed by
ultrasonography (Acuson Antares, Siemens, Erlangen, Germany) or previous surgical
treatment. Aortic aneurysm was deﬁned as a maximum aortic diameter of at least
3 cm, measured in any direction, detected by ultrasonography or CT (SOMATOM
Deﬁnition, Siemens, Erlangen, Germany) or previous surgical treatment. If patients
had stenotic and aneurysmal ECAD, they were classiﬁed according to the most lim-
iting disease. The most limiting disease was considered the disease one which (had)
needed surgical treatment.
Exclusion criteria were history or complaints of symptomatic CAD, unable to sus-
tain a breath-hold for 25 seconds, asthma, contra-indications to APMR examina-
tion, contra-indications to adenosine, unable to remain in supine position for at least
60 minutes, signiﬁcant aortic valve stenosis, contra-indications to iodine contrast
agent, renal insuﬃciency (serum creatinine ≥120 mmol/l), severe arterial hyper-
tension (>220/120 mmHg), extreme obesity (body mass index [BMI] >40 kg/m2),
severe physical deterioration due to concomitant disease, or inability to give informed
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consent. The study was approved by the local institutional review boards. All patients
gave written informed consent.
In the current investigation, only patients from the University Medical Center Gronin-
gen were included, as inclusion at the latter center is still ongoing and the inclusion
rate at the latter center has so far been low, which could introduce bias. A ﬂow chart
of the study is given in Figure 3.1. Of the invited patients, over 70 % agreed to
participate. The primary endpoints were deﬁned as signiﬁcant CAD (calcium score
>1,000, cCTA-detected coronary stenosis ≥50 %, or APMR-detected perfusion de-
fects. Secondary endpoint was referral to a cardiologist.
At baseline, patients completed a questionnaire on ECAD, risk factors, medication
use, medical history, and family history (1st degree relatives <60 years). Height,
weight and blood pressure were measured. Total cholesterol, high density lipopro-
teins (HDL), low density lipoproteins (LDL), triglycerides, glucose, serum creatinine
and high-sensitive C-reactive protein (hsCRP) were measured at the local laboratory.
Hypertension was classiﬁed as systolic blood pressure ≥140 mmHg and/or diastolic
blood pressure ≥90 mmHg, or medication for hypertension. Dyslipidaemia was clas-
siﬁed as LDL-cholesterol >4.0 mmol/l, HDL-cholesterol <1.2 mmol/l (female) or
<1.0 mmol/l (male), triglycerides >4.0 mmol/l, or current lipid-lowering medication.
Diabetes was classiﬁed as fasting plasma glucose >7.0 mmol/l, known diabetes or
medication for diabetes. Also an electrocardiogram (ECG) was performed.
CCTA imaging
A dual-source CT scanner was used (SOMATOMDeﬁnition, Siemens, Erlangen, Ger-
many). First, a non-contrast-enhanced calcium score was performed, using prospec-
tive ECG-triggering, starting 15 mm cranial of the most superior coronary artery to
15 mm caudal of the inferior border of the heart. Calcium score calculation was
performed according to Agatston.19 Next, cCTA was performed using a standardized
protocol. The following scanning parameters were used: slice acquisition 64 × 2 ×
0.6 mm, gantry rotation time 330 ms, tube voltage 120 kV, BMI-adapted tube cur-
rent (CARE Dose, Siemens, Erlangen, Germany). Calcium scoring was used as scout
radiograph. A beta-blocker (metoprolol 5 to 20 mg, depending on heart rate) was
administered intravenously to patients with a heart rate over 65 beats per minute,
under blood pressure monitoring. Nitroglycerine was administered sublingually. Heart
rate and ECG were continuously monitored. As contrast material iomeprol (Iomeron
400, 400 mg/ml, Bracco, Buckinghamshire, UK) was used at a ﬂow rate adjusted
for BMI.
Analysis of calcium scoring and cCTA was performed by the attending radiologist,
with at least 5 years experience in cardiac imaging. According to clinical practice, a
single radiologist read the cCTA; cCTA acquisition and evaluation were performed
prior to APMR. In a 15-segment modiﬁed American Heart Association classiﬁca-
tion all segments, independent of image quality, were evaluated visually. Segments
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were classiﬁed as having signiﬁcant stenosis when there was ≥50 % lumen diameter
reduction. Patients did not undergo cCTA if the calcium score exceeded 1,000.
APMR imaging
APMR was performed with a 1.5-Tesla scanner (Avanto, Siemens, Erlangen, Ger-
many). Patients were instructed to refrain from caﬀeine 24 hours prior to examina-
tion. Medication interfering with adenosine was stopped 5 days prior to examination.
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During the procedure, ECG was continuously monitored. Blood pressure and heart
rate were recorded at baseline and every minute during adenosine infusion.
After acquisition of scout views for determination of the standard orientations of the
heart, 3 parallel short-axis slices (basal, mid-papillary and apical) were planned for
perfusion imaging. Hyperaemia was induced by continuous intravenous infusion of
140 µg/kg/min adenosine. After 3 minutes, a bolus of gadolinium contrast material
(infusion rate and contrast material deﬁned by local practice) was injected, followed
by perfusion imaging. Minimally 5 minutes after perfusion images, MR sequences
were repeated for rest imaging. Ten minutes after the last gadolinium injection,
delayed contrast enhancement images were acquired to assess possible myocardial
infarctions.
Analysis of the APMR was performed by the attending radiologist, with at least
5 years experience in cardiac imaging, using a 16-segment model. APMR was con-
sidered positive if a perfusion abnormality was present in at least two segments at
consecutive planes during adenosine stress imaging, with normalization at rest.
Referral to Cardiologist
In the GROUND2 study, we used current guidelines to establish criteria for referral
to a cardiologist for further work-up and treatment.10,20 Patients were referred to a
cardiologist if a left main coronary artery stenosis or equivalent (stenosis in proximal
left anterior descending artery and circumﬂex artery) was detected on cCTA, or if
APMR showed signs of reversible myocardial ischemia. In case of incidental non-
cardiac ﬁndings, patients were referred to a dedicated physician. Invasive coronary
angiography was performed according to standard procedures using a transfemoral
or transradial approach. Multiple projections were obtained as deemed necessary by
the angiographer. Coronary angiography images were assessed visually for diameter
stenosis; no fractional ﬂow reserve measurement was performed. Further work-up
and treatment choice was left to the discretion of the cardiologist.
Statistical analysis
Patients with stenotic ECAD (PAOD, carotid stenosis) were grouped and compared
with patients with aneurysmal ECAD. Descriptive statistics were calculated as mean
with standard deviation or median with interquartile range and absolute numbers
and percentages in case of dichotomous variables. The Student t-test was used for
normally distributed, Kruskal-Wallis test for non-normally distributed and the Chi-
square test for categorical variables. All statistical analyses were performed using
PASW Statistics version 18.0.3 (SPSS Inc, Chicago, USA). All statistical tests are
two-sided and a P -value of <0.05 was considered to be statistically signiﬁcant. The
study had 80 % power to determine a prevalence of 30 % CAD as compared with
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20 % in the overall population.6
3.3 Results
Between December 2009 and March 2012, 111 patients were included. In total, 68
patients had PAOD, 16 carotid stenosis and 27 abdominal aortic aneurysm. Of the
patients with PAOD, 3 were asymptomatic following surgery, the remainder had at
least Fontaine 2. Carotid stenosis was symptomatic in 14 of 16 patients (87.5 %).
Of the patients with an aortic aneurysm, 59.3 % had been interventionally treated.
General characteristics are shown in Table 3.1. Ninety percent of the patients with
stenotic ECAD had at least two risk factors, versus 81 % of the patients with aneurys-
mal ECAD (P = 0.21).
Table 3.1: Baseline characteristics of all patients and comparison of baseline characteristics
in patients with stenotic versus aneurysmal extra-cardiac arterial disease







Age (years) 65.2 ± 7.7 64.3 ± 7.6 67.9 ± 7.3 0.03
Gender (male) 84 (75.7 %) 61 (72.6 %) 23 (85.2 %) 0.08







Hypertension 92 (82.9 %) 72 (85.7 %) 20 (74.1 %) 0.16
Systolic blood pressure
(mmHg)
141 ± 24 142 ± 24 134 ± 25 0.13
Diastolic blood pressure
(mmHg)
78 ± 11 78 ± 10 79 ± 11 0.67
Dyslipidemia 104 (93.7 %) 78 (92.6 %) 26 (96.3 %) 0.52
Total cholesterol (mmol/l) 4.7 ± 1.9 4.7 ± 1.0 4.6 ± 1.3 0.59
Triglycerides (mmol/l) 2.06 ± 1.88 1.92 ± 1.71 2.47 ± 2.33 0.20
HDL-cholesterol (mmol/l) 1.3 ± 0.4 1.3 ± 0.4 1.2 ± 0.4 0.13
LDL-cholesterol (mmol/l) 2.7 ± 0.9 2.8 ± 0.9 2.6 ± 1.0 0.37
Diabetes mellitus 15 (13.5 %) 14 (16.7 %) 1 (3.7 %) 0.09
Glucose (mmol/l) 6.0 ± 1.9 6.1 ± 2.1 5.6 ± 1.0 0.22
Creatinin (mmol/l) 80 ± 18 79 ± 17 84 ± 21 0.24
High-sensitive CRP (mg/l) 2.1 [0.9-7.0] 1.9 [0.8-6.2] 3.8 [1.1-11.8] 0.045
Smoking 0.17
Current 37 (33.3 %) 32 (38.1 %) 5 (18.5 %)
Past 65 (58.6 %) 46 (57.1 %) 19 (70.4 %)
Never 9 (8.1 %) 6 (7.1 %) 3 (11.1 %)
Values are mean ± SD, median [interquartile range] or number of subjects (percentage).
HDL High density lipoprotein LDL low density lipoprotein CRP C-reactive protein.
Table 3.2 shows characteristics regarding family history. Aneurysmal ECAD was more
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Table 3.2: Baseline characteristics of all patients and comparison of familial history in patients
with stenotic versus aneurysmal extra-cardiac arterial disease







High blood pressure 51 (45.9 %) 39 (46.2 %) 12 (44.4 %) 0.86
Diabetes 25 (22.5 %) 18 (21.4 %) 7 (25.9 %) 0.62
High cholesterol 35 (31.5 %) 30 (35.7 %) 5 (18.5 %) 0.09
Stroke 15 (13.5 %) 10 (11.9 %) 5 (18.5 %) 0.38
Myocardial infarction 23 (20.7 %) 19 (22.6 %) 4 (14.8 %) 0.38
Intermittent claudication 31 (27.9 %) 24 (28.6 %) 7 (25.9 %) 0.79
Dilatation of an artery 9 (8.1 %) 2 (2.4 %) 7 (25.9 %) <0.01
Narrowing of an artery 18 (16.2 %) 16 (19.0 %) 2 (7.4 %) 0.15
Values are number of subjects (percentage).
prevalent in the family of patients with aortic aneurysm, while there was a tendency
(P = 0.15) for higher prevalence of stenotic ECAD in family of patients with stenotic
ECAD.
CT was performed in all patients. Median calcium score was 239.5 for stenotic ECAD
and 209.5 for aneurysmal ECAD (P = 0.21). This is demonstrated in Figure 3.2.
Twenty-three patients did not undergo cCTA because their calcium scores were above
1,000. The results from cCTA were not signiﬁcantly diﬀerent between the two groups
of patients (Table 3.3). After cCTA or calcium scoring, APMR was performed in
83 patients (74.8 %; Table 3.4). Ischemia was present in 8 patients (12.3 %) with
stenotic ECAD and in 2 patients (11.1 %) with aneurysmal ECAD (P = 0.41). The
prevalence of silent severe CAD was 56.8 % (95 % conﬁdence interval 47.5-66.0 %).
The waiting period between CT and APMR ranged from 1 to 6 months (70 % <2
months).
In total, 22 patients were referred to a cardiologist (Table 3.5). There was no sig-
niﬁcant diﬀerence in referral percentage between the two groups of patients. Six
patients with positive cCTA and 9 patients with positive APMR underwent diagnos-
tic coronary angiography. One patient did not have a signiﬁcant stenosis on invasive
coronary angiography. Of patients referred to the cardiologist, 9 received a coronary
intervention (42.9 %). Two patients were advised to undergo surgery, but preferred
PCI. Three more patients had a severe coronary stenosis without possibility for in-
tervention. They were treated by maximum conservative treatment. Further details
are shown in Table 3.3. Figures 3.3 and 3.4 show examples of referred patients. Of
the 2 patients referred with aortic valve stenosis, it was severe in 1 patient. This
patient was treated by transcatheter aortic valve implantation. In one patient with a
surgically corrected aortic aneurysm a new aneurysm was found. Two patients had
pulmonary lesions, comprising granulomas and previously unknown sarcoidosis. No
malignancies were found.
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Figure 3.2: Distribution of calcium score categories in stenotic and aneurysmal ECAD
3.4 Discussion
This is one of the ﬁrst studies in extra-cardiac arterial disease patients assessing
the presence of asymptomatic CAD using non-invasive screening. In ECAD patients
without cardiac symptoms or history, we found a high percentage of silent, severe
coronary artery disease on non-invasive imaging. Referral to a cardiologist because
of severe CAD was deemed necessary in nearly one ﬁfth of all patients, resulting
in coronary intervention in 9.0 % of all patients. CT showed signiﬁcant coronary
stenosis in a third, while an additional 21 % of patients had a very high calcium score
(>1,000). This does not imply CAD is present in all patients with ECAD. There was
a small, but distinct group of patients without any coronary calciﬁcation or stenosis
(7.2 %).
ECAD patients have a high risk of coronary events. Leng et al. found that 7 %
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Figure 3.3: Example of a 76-year-old patient with PAOD. (a) Coronary CT angiography
image. White arrow points to a mixed plaque in the proximal left anterior descending artery,
with stenosis of the lumen. Calcium score was 553. (b) Short axis image of the adeno-
sine perfusion MRI examination. White arrows point to a subendocardial perfusion defect
in the septal wall, during stress. The perfusion defect was not present in the rest series,
thus indicating inducible ischemia. (c) Invasive coronary angiography image of the left coro-
nary arteries. Black arrow points to a signiﬁcant stenosis, corresponding with the location
seen on CT. (d) Invasive coronary angiography image after intervention. Good result after
percutaneous coronary intervention with stent placement.
(a) Coronary CT angiography (b) Adenosine Perfusion MRI
(c) Invasive Coronary Angiography (d) After Percutaneous Coronary Intervention
of patients with ECAD suﬀered a myocardial infarction within 5 years in the Ed-
inburgh Artery Study, a cohort study of 1,592 subjects.21 In a large study, 1,000
patients with either stenotic or aneurysmal arterial disease, considered for elective
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Figure 3.4: Example of a 68-year-old patient with PAOD. (a) Coronary CT angiography.
White arrow points to a soft plaque in the proximal right coronary artery, narrowing the
lumen more than 50 %. (b) Short axis image of the adenosine perfusion MRI examination.
White arrow points to a perfusion defect of the inferior wall during stress. This perfusion was
not present in rest, indicating reversible ischemia. (c) Invasive coronary angiography image
of the right coronary artery. The right coronary artery is proximally occluded (white arrow).
No percutaneous intervention was possible at this stage. Due to the asymptomatic status
and good collateral circulation (visible as contrast ﬁlling distal to the occlusion), no surgery
was performed.
(a) Coronary CT angiography (b) Adenosine Perfusion MRI
(c) Invasive Coronary Angiography
vascular reconstruction, underwent invasive coronary angiography. Approximately 30
of the patients had signiﬁcant CAD, warranting coronary revascularization. The au-
thors concluded that non-invasive cardiac screening could be important to assess the
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Coronary CT angiography 0.88
No calcium or stenosis 7 8 (7.2 %) 6 (7.1 %) 2 (7.4 %)
No signiﬁcant stenosis 40 (36.0 %) 29 (34.5 %) 11 (40.7 %)
Signiﬁcant Stenosis 40 (36.0 %) 32 (38.1 %) 8 (29.6 %)
Calcium score >1,000 AU 23 (20.7 %) 17 (20.2 %) 6 (22.2 %)
Magnetic resonance imaging 83 (74.8 %) 65 (77.4 %) 18 (66.7 %) 0.41
No ischemia 73 (88.0 %) 57 (87.7 %) 16 (88.9 %)
Ischemia 10 (12.0 %) 8 (12.3 %) 2 (11.1 %)
Cardiologist 22 (19.8 %) 16 (19.0 %) 6 (22.2 %) 0.66
Invasive angiography 16 (72.7 %) 13 (81.3 %) 3 (50.0 %)
Conservative treatment 9 (40.9 %) 6 (37.5 %) 3 (50.0 %)
Intervention 10 (45.5 %) 7 (43.7 %) 3 (50.0 %)
PCI 7 (70.0 %) 7 (100 %) 0 (0.0 %)
CABG 2 (20.0 %) 0 (0.0 %) 2 (66.7 %)
Other 1 (10.0 %) 0 (0.0 %) 1 (33.3 %)
No treatment possible 3 (14.2 %) 3 (18.8 %) 0 (0.0 %)
Values are median [interquartile range] or number of subjects (percentage).
CT Computed tomography AU Agatston units PCI percutaneous coronary intervention
CABG coronary artery bypass graft.
necessity for invasive coronary angiography.6,22
Little is known about the prevalence of severe, silent CAD. This is mainly because
previously, invasive coronary angiography was the only method to detect coronary
stenosis. This procedure is not without complications and therefore not usually per-
formed in patients without clinical signs of CAD. Only recently, CT and MRI have
emerged as non-invasive imaging methods for imaging of the coronary arteries and
myocardium. A previous study (n = 3,263) on the association between ECAD en
CAD, examined with intravascular ultrasound, revealed that patients with ECAD had
more extensive and calciﬁed CAD, impaired arterial remodelling and greater disease
progression, compared with patients without ECAD.23 This suggests that patients
with ECAD could have a more aggressive form of systemic atherosclerosis. ECAD
may actually directly promote the development and progression of CAD. Two mech-
anisms can be suggested. First, ECAD limits mobility, not only in patients with
PAOD, but also in other forms of ECAD. This may lead to a lower frequency of
exercise-induced cardiac symptoms in ECAD patients with CAD. Second, ECAD
could have a direct relation with myocardial ischemia through impaired peripheral
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endothelial function with reduced vasodilatation and vasoconstriction in response to
stress.24,25 A beneﬁcial eﬀect from risk factor reduction on atherosclerosis progres-
sion was demonstrated by Hussein et al.23 Risk factor modiﬁcation with lifestyle
changes such as smoking cessation and optimal medical treatment with statins,
beta-blockade and anti-platelet therapy is recommended, especially in patients with
several cardiac risk factors undergoing high-risk vascular surgery, although only peri-
operatively for aneurysm surgery.26,27 Unfortunately, adherence to the guidelines re-
garding risk factor reduction is often performed less reliably in patients with ECAD
than in patients with proven CAD.24,25
The Coronary Artery Revascularization Prophylaxis study showed no overall survival
beneﬁt from pre-operative coronary revascularization before elective vascular surgery
in patients with single- or multi-vessel CAD. However, pre-operative coronary revas-
cularization did positively impact survival in patients with unprotected left main coro-
nary artery stenosis, which was present in 4.6 % of patients.28 Another study stated
that in patients undergoing elective vascular surgery, risk stratiﬁcation screening for
CAD is indicated, possibly with non-invasive imaging.26 Patients who have clinical
atherosclerotic disease, such as ECAD, are also considered to be at high risk of
CAD.29 Drawback of the available risk stratiﬁcation models for cardiovascular risk
is the relative inaccuracy, for example to predict peri-operative death after elective
open abdominal aortic aneurysm repair.30 Thus, non-invasive imaging of CAD can be
an important addition to risk stratiﬁcation in appropriately selected ECAD patients.
The value of coronary assessment prior to carotid endarteriectomy has previously
been studied. Illuminati et al.12 found a reduction of postoperative cardiac ischemic
events when invasive coronary angiography, if necessary combined with percutaneous
coronary intervention, was performed preoperatively. This was also beneﬁcial in car-
diac asymptomatic patients, and supports cardiac screening prior to major vascular
surgery.22 Coronary stenosis was found in about a third of patients, in line with our
results. While in this study only preoperative patients were included, we evaluated a
broader range of ECAD patients. It is unknown if screening for CAD in the entire
population of ECAD patients is recommendable. Current guidelines do not advocate
routine CAD-imaging in all ECAD patients. While our study shows silent, severe
CAD in a considerable part of ECAD patients, a beneﬁcial eﬀect of CAD screening
by non-invasive imaging on occurrence of coronary events in the following years still
needs to be proven. For this, large trials should be performed.
There are limitations to our study that must be mentioned. First of all, the study
population was relatively small. Inclusion of vascular patients for our cardiac imaging
study was complicated by the fact that many of these patients already had symp-
tomatic CAD or comorbidity. Probably, this also at least partly explains the lack of
studies on non-invasive cardiac imaging in this patient group, and adds to the value of
the current study. We estimate that approximately 10 % of patients were considered
suitable for inclusion. It is probable that the setting of the tertiary, university hospital
has contributed to low inclusion rate, as the patients who are treated in this center
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Table 3.4: Reasons for not performing adenosine perfusion magnetic resonance imaging
(APMR)
APMR not performed 28
Not possible (i.e. aortic valvular stenosis, aortic stent) 11
Zero calcium score and no coronary plaque 8
Primary referral to cardiologist after CT 4
Refusal to undergo APMR 3
Endpoint reached (death or myocardial infarction) 2
CT Computed tomography.
are more often complicated cases. Thus, it is likely that the inclusion rate would
be substantially higher in a general hospital. Secondly, although the two vascular
patient groups are not signiﬁcantly diﬀerent in risk factors, they are diﬀerent in size.
The group with aneurysmal vascular disease was smaller. This can be explained by
the fact that stenotic atherosclerosis is much more prevalent in the vascular surgery
outpatient clinic, compared with aortic aneurysms. Lastly, at this stage follow-up of
the patient population is not known.
Table 3.5: Reasons for referral to cardiologist
Referral Cardiologist 22
Extreme high calcium score 1
Left main coronary artery stenosis 1
Signiﬁcant stenosis cCTA, without possibility APMR 4
Aortic valvular stenosis 2
Perfusion defect APMR 10
Atrial myxoma 1
Cardiac complaints 3
Values are absolute numbers.
cCTA Coronary computed tomography angiography APMR adenosine perfusion magnetic
resonance imaging.
This study is one of the ﬁrst to demonstrate a high prevalence of silent severe coro-
nary artery disease by non-invasive imaging in patients with extra-cardiac arterial
disease. The rate of CAD was not signiﬁcantly diﬀerent in patients with stenotic
compared with aneurysmal ECAD. Further studies may show screening in these high
risk patients to be beneﬁciary.
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Hemodynamic significance of coronary
stenosis by vessel attenuation









Objectives We assessed the association between corrected contrast opaciﬁcation
(CCO) based on coronary computed tomography angiography (cCTA) and inducible
ischemia by adenosine perfusion magnetic resonance imaging (APMR).
Methods Sixty cardiac asymptomatic patients with extra-cardiac arterial disease
(mean age 64.4 ± 7.7 years; 78 % male) underwent cCTA and APMR. Luminal
CT attenuation values (Hounsﬁeld Units) were measured in coronary arteries from
proximal to distal, with additional measurements across sites with >50 % lumen
stenosis. CCO was calculated by dividing coronary CT attenuation by descending
aorta CT attenuation. A reversible perfusion defect on APMR was considered as
myocardial ischemia.
Results In total, 169 coronary stenoses were found. Seven patients had 8 perfu-
sion defects on APMR, with 11 stenoses in corresponding vessels. CCO decrease
across stenoses with hemodynamic signiﬁcance was 0.144 ± 0.112 compared to
0.047 ± 0.104 across stenoses without hemodynamic signiﬁcance (P = 0.003). CCO
decrease in lesions with and without anatomical stenosis was similar (0.054 ± 0.116
versus 0.052 ± 0.101; P = 0.89). Using 0.20 as preliminary CCO decrease cut-oﬀ,
hemodynamic signiﬁcance would be excluded in 82.9 % of anatomical stenoses.
Conclusion CCO decrease across coronary stenosis is associated with myocardial
ischemia on APMR. CCO based on common cCTA data is a novel method to assess
hemodynamic signiﬁcance of anatomical stenosis.




Computed tomography (CT) has high diagnostic accuracy for the detection and
exclusion of coronary artery disease (CAD), compared with invasive coronary angio-
graphy.1,2 Coronary stenosis detected on coronary CT angiography (cCTA), however,
shows poor correlation with lesion-speciﬁc and global myocardial ischemia.1,2 In the
cath lab, fractional ﬂow reserve (FFR) is used to assess the functional signiﬁcance of
coronary stenosis.3 This lesion-speciﬁc index reﬂects the eﬀect of stenosis on myocar-
dial perfusion. However, FFR measurement is an invasive procedure with associated
costs, and is only performed in symptomatic patients undergoing invasive coronary
angiography. Recent imaging techniques can assess the hemodynamic signiﬁcance
of CAD without the risk associated with an invasive procedure. Adenosine perfusion
magnetic resonance imaging (APMR) and positron emission tomography are safe
and preferable non-invasive alternatives for vessel-speciﬁc ischemia detection with
similar high diagnostic accuracy.4,5 APMR has an excellent sensitivity and speciﬁcity
of 91 and 94 % respectively, as compared with FFR.6
In view of the increased use of cCTA to assess CAD, it would be extremely valuable
if this same non-invasive test could determine the hemodynamic signiﬁcance of the
anatomical stenoses that are readily detected. Recently, an estimate of coronary
ﬂow was obtained using common cCTA data. In calculations based on cCTA, re-
duced ﬂow across an intermediate-grade coronary stenosis points to the presence of
hemodynamically signiﬁcant CAD. Two multicenter studies have demonstrated the
preliminary clinical value of this approach, using computational ﬂuid dynamics.7–9This
method involves a lengthy and complicated computation, potentially hindering its in-
troduction in clinical practice. A simpler calculation named the corrected contrast
opaciﬁcation (CCO)10–12 can also estimate coronary artery ﬂow. So far, clinical stu-
dies have compared CT-derived ﬂow measurements with FFR measurements. Due
to the nature of FFR evaluation, these studies involved a selected population of
symptomatic patients. This is the ﬁrst study in which CT-derived CCO is compared
with non-invasive imaging of functionally signiﬁcant CAD. The aim of this study, in a
high-risk, cardiac asymptomatic population, is to investigate the association between
CCO as estimate of coronary ﬂow and ischemia detection by APMR.
4.2 Materials and Methods
Patients
This is a substudy of the prospective GROUND2 study, in which cardiac asymp-
tomatic patients with extra-cardiac arterial disease (ECAD) underwent non-invasive
cardiac imaging.13 This substudy included sixty patients who had undergone cCTA
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and APMR at our institution. The study protocol was approved by the institutional
review board of the University Medical Center Groningen; all patients gave written
informed consent.
Computed tomography
CT scanning was performed using a dual-source CT scanner (SOMATOM Deﬁnition,
Siemens, Erlangen, Germany). CCTA was performed in spiral mode, with retrospec-
tive electrocardiographic (ECG)-gating. Scanning parameters were: 32 × 0.6 mm
collimation, image acquisition 64 × 2 × 0.6 mm by z-ﬂying spot, increment 0.4 mm,
330 ms rotation time, tube voltage and current according to weight, tube current
modulation on (CARE Dose, Siemens, Erlangen, Germany), pitch depending on heart
rate, ﬁeld-of-view 205 mm. Images were reconstructed as consecutive 0.6 mm slices.
Coronary evaluation was performed by the attending radiologist, with at least 5 years
of experience in cardiac imaging. According to clinical practice, a single radiologist
read the cCTA; cCTA acquisition and evaluation were performed prior to APMR.
Axial slices as well as curved multi-planar reconstruction images were analysed, using
Syngo software (Siemens, Erlangen, Germany). Using the 15-segment modiﬁed AHA
classiﬁcation,14 coronary segments were evaluated visually, independent of image
quality. Segments were classiﬁed as having anatomically signiﬁcant stenosis when
there was >50 % lumen diameter reduction, compared to the proximal lumen dia-
meter. In case of signiﬁcant stenosis, distinction was made between 50-70 % and
>70 % stenosis.
CT contrast opacification
Coronary luminal attenuation values (Hounsﬁeld Units [HU]) were assessed semi-
automatically on curved multi-planar reconstruction images, using Aquarius iNtuition
software version 4.4.11Beta (TeraRecon, San Mateo, USA). Segments were excluded
from analysis when diameter was <1.5 mm. Vessels were excluded when calciﬁcation
at the origin prohibited semi-automated measurements. No vessels were excluded
based on stenosis severity. In remaining coronary arteries, HU-measurements were
performed at the origin, and in the proximal, mid and distal segment. In case of
>50 % stenosis, four additional HU-values were measured, two HU-measurements
proximal and two distal to the stenosis (within 2 cm of the lesion). Examples of
levels of coronary HU-measurements are shown in Figure 4.1 and 4.2. Length, plaque
composition and segmental location of stenosis were recorded.
Normal coronary arteries show a gradient in opaciﬁcation along their course.11,15
Therefore, we measured the descending aorta attenuation at the same height as the
proximal, mid and distal segments of the coronary arteries, to approach the CCO
(Figure 4.1).12 We calculated the CCO by dividing coronary attenuation by descen-
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Figure 4.1: Volume-rendered computed tomography (CT) image of the heart, showing the
locations of attenuation measurements at the origin (A), proximal (B), mid (C) and distal
(D) segment in the right coronary artery (left frame). The right frame demonstrates the














ding aorta attenuation. We used the lower of the two measurements surrounding
stenosis to calculate the CCO decrease across stenosis. When a vessel ran perpen-
dicular to the aorta, measurements were corrected at the same level, following Chow
et al.12
Magnetic resonance imaging
APMR was performed with a 1.5-Tesla scanner (Avanto, Siemens, Erlangen, Ger-
many). Patients were instructed to refrain from caﬀeine for at least 24 hours prior to
the examination. Medication interfering with adenosine was stopped ﬁve days prior
to the examination. During the procedure, ECG was continuously monitored. Blood
pressure and heart rate were recorded at baseline and every minute during adenosine
infusion. APMR analysis was performed by the attending radiologist, with at least
5 years of experience in cardiac imaging, using the 16 segment model. APMR was
considered positive if a perfusion defect was present in at least two segments at
consecutive planes during adenosine perfusion imaging, with normalization in rest.16
The most likely culprit artery for the perfusion defect was assessed. If more than one
stenosis exists in the culprit artery, the speciﬁc stenosis causing ischemia is not always
identiﬁable. Therefore, in a patient with perfusion defect, we labelled all anatomically
signiﬁcant stenoses in the culprit artery as hemodynamically signiﬁcant.
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Figure 4.2: Curved multiplanar reconstruction of the left anterior descending artery, with a
stenosis in the proximal segment. Measurements before (B1 and B2) and after (A1 and A2)
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Statistical analysis
For numerical values, the mean ± standard deviation (SD) was calculated; median
[25th, 75th percentile] when the distribution was observed non-normal. For categorical
variables, frequency with percentage was provided. To test diﬀerences between pa-
tients with positive and negative APMR, t-test was applied for continuous, normally
distributed variables; Mann-Whitney U test for non-normally distributed numerical
variables, and Chi-square test for categorical variables. The Mann-Whitney U test
was used to compare diﬀerences in CCO gradients between normal and stenotic ar-
teries. Spearman correlation coeﬃcients were calculated to examine the relationship
between CCO and stenosis characteristics. Linear regression was applied with CCO
decrease as outcome to test the eﬀect of perfusion defect, corrected for length,
composition and location of stenosis. Analyses were performed by vessel and by
stenosis. To assess inter-reader agreement for CCO measurement, 20 randomly se-
lected cCTA scans were evaluated by a second reader, and the intraclass correlation
coeﬃcient (ICC) was calculated. Consistency of agreement across coronary arteries
was assessed by the likelihood ratio test. In Bland-Altman plot analysis, we assessed
diﬀerence in CCO between the readers. Post-hoc power analysis was performed on
the estimated eﬀect size. Finally, receiver-operator characteristics (ROC) analyses
were created to determine a potential cut-oﬀ value for determining hemodynamic sig-
niﬁcance of coronary stenosis. Statistical analyses were performed using IBM SPSS
Statistics version 20.0.0.1 (SPSS Inc, Chicago, USA) or SAS version 9.3 (SAS In-
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stitute Inc, Cary, USA). Statistical tests were two-sided. A P -value of <0.05 was
considered statistically signiﬁcant.
4.3 Results
Overview of cohort in terms of patients and vessels
Sixty patients (mean age 64.4 ± 7.7 years; 78 % male) were included. Of these, 10
had no coronary plaques on cCTA, 21 had plaques causing 0-50 % stenosis and 29
had >50 % stenosis. Seven patients had a positive APMR test, with eight perfusion
defects. Characteristics did not diﬀer signiﬁcantly between patients with and without
ischemia on APMR. Only the percentage of diabetics was higher among patients with
perfusion defect (Table 4.1).
Figure 4.3 gives an overview of the coronary arteries. Twenty-eight of the 180
coronary arteries could not be included in CCO analysis, due to inability to measure
attenuation at the origin or distally. Anatomical stenoses were present in 87 of
the 152 remaining vessels. Eight stenotic arteries showed a perfusion defect in the
corresponding vascular territory.
Anatomically and hemodynamically significant stenoses
In total, 169 anatomical stenoses were found. Seventy-seven were located in the
left anterior descending artery (LAD), 32 in the circumﬂex artery (LCX) and 60 in
the right coronary artery (RCA). One stenosis was caused by soft plaque, 59 by
partially calciﬁed plaque, and 109 by calciﬁed plaque. Of the anatomical stenoses,
68 narrowed the lumen diameter >50 %, and 14 of these >70 %. Stenoses ≤50 %
showed no hemodynamic signiﬁcance. Eleven >50 % stenoses were present in the
vessel territories with ischemia on APMR. Information about the stenoses in culprit
vessels is provided in Table 4.2. Culprit arteries contained 7 partially calciﬁed and
4 calciﬁed plaques causing >50 % stenosis, compared to 1 soft plaque, 52 partially
calciﬁed, and 105 calciﬁed in non-culprit arteries (P = 0.12). Overall stenosis length
and number of stenoses were not signiﬁcantly diﬀerent for hemodynamically versus
hemodynamically non-signiﬁcant stenoses (length: 11.9 mm [25th, 75th percentile:
7.41, 30.90] versus 9.14 mm [6.01, 14.88], P = 0.17; number: 1.4 ± 0.7 versus
1.7 ± 0.9; P = 0.32).
Contrast attenuation in aorta and coronary arteries
Median attenuation values in the descending aorta were 351.5 [300.8, 400.3] HU,
332.0 [288.3, 386.5] HU and 316.5 [266.8, 392.8] HU at the level of proximal, mid
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Table 4.1: Characteristics of all patients and comparison of characteristics between patients
with hemodynamically signiﬁcant versus hemodynamically non-signiﬁcant coronary artery dis-











Age (years) 64.4 ± 7.7 63.9 ± 7.5 68.7 ± 8.5 0.12
Gender (male) 47 (78.3 %) 41 (77.4 %) 6 (85.7 %) 0.61
Body mass index 26.3 ± 3.6 26.5 ± 3.7 25.9 ± 3.8 0.68
Hypertension 49 (81.7 %) 42 (79.2 %) 7 (100 %) 0.18
Systolic BP (mmHg) 140 ± 23 140 ± 24 134 ± 13 0.52
Diastolic BP (mmHg) 80 ± 10 80 ± 10 75 ± 9 0.19
Antihypertensive treatment 42 (70.0 %) 37 (69.8 %) 5 (71.4 %) 0.93
Dyslipidemia 54 (90.0 %) 47 (88.7 %) 7 (100 %) 0.34








HDL-cholesterol (mmol/l) 1.2 [0.9-1.4] 1.2 [0.9-1.5] 1.0 [0.8-1.2] 0.32
LDL-cholesterol (mmol/l) 2.8 [2.2-3.6] 2.5 [2.2-3.6] 3.2 [2.9-4.1] 0.13
Cholesterol lowering treatment 46 (76.7 %) 42 (79.4 %) 4 (57.1 %) 0.19
Diabetes mellitus 5 (8.3 %) 3 (5.7 %) 2 (28.6 %) 0.04
Glucose (mmol/l) 5.4 [5.0-6.0] 5.3 [5.0-6.0] 5.5 [4.8-7.0] 0.80
















Number of lesions 9.9 ± 6.4 9.7 ± 6.5 12.5 ± 5.8 0.41
Smoking 0.21
Current 25 (41.7 %) 23 (43.4 %) 2 (28.6 %)
Past 29 (48.3 %) 26 (49.1 %) 3 (42.9 %)
Never 6 (10.0 %) 4 (7.5 %) 2 (28.6 %)
ECAD 0.11
PAOD 35 (58.3 %) 31 (58.5 %) 4 (57.1 %)
Carotid stenosis 11 (18.3 %) 8 (15.1 %) 3 (42.9 %)
AAA 14 (23.3 %) 14 (26.4 %) 0 (0.0 %)
Values are mean ± SD, median [interquartile range] or number of subjects (percentage).
APMR Adenosine perfusion magnetic resonance imaging BP blood pressure HDL high den-
sity lipoprotein LDL low density lipoprotein CRP C-reactive protein ECAD extra-cardiac
arterial disease PAOD peripheral arterial occlusive disease AAA abdominal aortic aneurysm
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Figure 4.3: Overview of the coronary arteries included and excluded from the analyses, and
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and distal coronary segments, respectively. Median coronary contrast attenuation in
the proximal segments was 377.0 [332.0, 408.5] HU, and in the distal segments 316.0
[269.0, 371.0] HU. Decrease in contrast attenuation from origin to distal coronary
segment was 128.5 [99.3, 151.5] HU in vessels with hemodynamically signiﬁcant
stenosis and 60.5 [17.3, 115.8] HU in those without (P = 0.02). Decrease in vessels
with and without anatomical stenosis was 61.0 [18.0, 122.0] HU and 69.0 [18.0,
106.5] HU, respectively (P = 0.72).
CCO in vessel-based analysis
Mean CCOorigin was 1.022 ± 0.080 in coronary arteries with hemodynamically sig-
niﬁcant stenosis, and 1.095 ± 0.177 in those without (P = 0.25). Mean CCOdistal
was 0.733 ± 0.131 and 1.028 ± 0.240, respectively (P <0.001). For anatomically
signiﬁcant stenosis, mean CCOorigin was 1.098 ± 0.175, and 1.084 ± 0.173 in ves-
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Shown are number of anatomic signiﬁcant stenoses on coronary computed tomography
angiography, location of perfusion defect on APMR and the cornoary artery expected for
causing the perfusion defect.
RCA Right coronary artery LCX circumﬂex coronary artery LAD left anterior descending
coronary artery prox proximal part of coronary artery mid middle part dist distal part
midventr midventricular
sels without (P = 0.60). Mean CCOdistal was 1.005 ± 0.220 and 1.030 ± 0.272,
respectively (P = 0.47). CCO decrease across vessels with hemodynamically signiﬁ-
cant stenoses was larger than in vessels without associated ischemia: 0.289 ± 0.132
versus 0.068 ± 0.258 (P = 0.02). In contrast, CCO decrease for vessels with and
without anatomical stenoses was not diﬀerent (0.097 ± 0.251 versus 0.055 ± 0.265;
P = 0.32). When limited to >70 % stenoses, the diﬀerence in CCO decrease for
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Figure 4.4: Example of decrease in corrected contrast opaciﬁcation (CCO) for 2 patients
with similar anatomical severity of stenosis, but with opposite result in adenosine perfusion
magnetic resonance imaging (APMR). A and B: 65-year old male patient with a 50-70
% stenosis in the circumﬂex artery. Contrast attenuation measurements above and below
the stenosis are shown; CCO decrease was 0.33 (A). the APMR revealed ischemia in the
inferolateral wall of the left ventricle, matching the circumﬂex artery (B). C and D: a 75-year
old male, also with a 50-70 % stenosis in the circumﬂex artery. CCO decrease was 0.09 (C),
no perfusion defect was present in APMR (D)
vessels with and without stenoses remained not signiﬁcant (0.114 ± 0.230 versus
0.070 ± 0.259; P = 0.18).
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CCO in stenosis-based analysis
Figure 4.4 shows an example of CCO results in patients with and without ischemia
on APMR, with similar anatomical stenosis severity. CCO decrease across stenoses
with hemodynamic signiﬁcance was larger than across those without (0.144 ± 0.112
and 0.047 ± 0.104; P = 0.003). In contrast, CCO decrease between lesions with
and without anatomically signiﬁcant stenosis was similar (0.054 ± 0.116 and 0.052
± 0.101, respectively; P = 0.89; Figure 4.5). Also stenosis composition did not diﬀer
signiﬁcantly (P = 0.47). However, plaques causing anatomically signiﬁcant stenosis
were relatively longer than non-obstructive plaques (11.9 [7.1, 24.7] mm versus 9.0
[5.6, 12.9] mm; P = 0.008).
Mean CCO decrease was 0.025 ± 0.106 across proximal stenoses, 0.077 ± 0.096
across stenoses in mid segments and 0.053± 0.122 across distal stenoses (P = 0.02).
When corrected for length, composition and location of stenosis, CCO decrease
remained signiﬁcantly diﬀerent for stenoses with versus those without hemodynamic
signiﬁcance (P = 0.003). For anatomically signiﬁcant stenoses, the CCO decrease
remained comparable in multivariable analysis (P = 0.90). Post-hoc power analysis
revealed a power of 84.9 % (using eﬀect size of 0.09645, standard error of 0.03203,
and degrees of freedom of 162).
Reproducibility and inter-reader variability
The overall ICC was 0.917, indicating excellent agreement. The ICC was 0.941,
0.872 and 0.964 for the LAD, LCX and RCA, respectively (P = 0.122). In Bland-
Altman analysis, the mean diﬀerence in CCO between readers was -0.0283 (95 %
CI: -0.222, 0.166).
ROC analysis
The sample size was insuﬃcient to derive a reliable cut-oﬀ point for CCO decrease
to detect ischemia. For a CCO decrease cut-oﬀ value between 0.20 and 0.25, the
sensitivity and speciﬁcity were relatively high (Figure 4.6). For instance, for a CCO
decrease of 0.20, the sensitivity was 87.5 % and the speciﬁcity was 71.5 %, while for
a CCO decrease of 0.25 the sensitivity was 75.0 % and the speciﬁcity was 79.2 %.
Based on CCO assessment, with a decrease in CCO of 0.20 as cut-oﬀ value, hemo-




In this study, CCO, derived from common cCTA data, showed a strong association
with hemodynamically signiﬁcant CAD, as determined by APMR. For mere anatomi-
cal stenoses, no such relationship was present. These results suggest that additional
information from standard cCTA data may assist in diﬀerentiation between a coronary
stenosis with and without hemodynamic signiﬁcance.
Figure 4.5: Boxplot of corrected contrast opaciﬁcation (CCO) decrease across stenoses
with and without anatomical and hemodynamic signiﬁcance. CCO decrease was signiﬁcant
for stenoses with versus those without hemodynamic signiﬁcance (P = 0.003), but not for





















Many coronary stenoses do not cause a relevant reduction in coronary ﬂow. It is dif-
ﬁcult to predict which anatomical stenosis causes ischemia.17,18 FFR, the reference
standard, is used during invasive angiography to assess hemodynamic signiﬁcance
and guide therapy.1,3 The correlation between anatomical stenosis detected by inva-
sive coronary angiography or cCTA, and FFR is poor.1,2 Thus, testing of functional
signiﬁcance of CAD is usually necessary to evaluate whether invasive treatment is
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needed, even in case of a positive cCTA. The ultimate goal is one non-invasive,
comprehensive imaging test for CAD.
There is increasing interest in coronary CT imaging, especially in symptomatic pa-
tients at intermediate CAD risk.19 Previously, cCTA only resulted in anatomical in-
formation on CAD. New technologies can yield an estimate of coronary ﬂow by mea-
suring changes in contrast attenuation.10 Chow et al. designed the CCO method,
as was also used in this study.12 In a proof-of-concept study, CCO diﬀerences were
useful to identify abnormal resting coronary ﬂow as assessed in invasive coronary
angiography.12 A second method based on manual HU measurements, the translu-
minal attenuation gradient (TAG) was described by Choi et al.20 TAG measurement
was found to improve the accuracy of severity classiﬁcation of calciﬁed stenoses by
cCTA, compared to invasive coronary angiography.20 However, a validation study of
both TAG and CCO showed only moderate associations between TAG/both measures
and hemodynamic stenoses as assessed with FFR.21 With the use of 320-MDCT,
the diagnostic accuracy of TAG was improved.22 However, without automated image
processing, TAG remains a time-consuming method.23 Two recent multicenter trials
used computational ﬂuid dynamics to estimate lesion-speciﬁc FFR,7,9,24 by calcula-
ting the ratio of coronary pressure and mean aortic pressure. It was demonstrated
that non-invasive FFR measurement was superior to cCTA for diagnosing ischemic
lesions.25 Drawbacks of this method are the extra patient information required, and
the lengthy calculation time.9
Previous studies on CT assessment of coronary ﬂow were performed in symptomatic
patients waiting for invasive coronary angiography, and comparison was made with
FFR. This population has a high pre-test probability for functionally signiﬁcant CAD,
which may have led to overoptimistic results. In contrast, our study included cardiac
asymptomatic patients at increased risk of CAD. We compared CCO to non-invasive
assessment of functionally signiﬁcant CAD by APMR, as invasive FFR measurement
in this asymptomatic population is unethical. The prevalence of silent ischemia by
APMR was considerable (12 %). Silent ischemia is a very relevant ﬁnding: asymp-
tomatic patients with positive ischemia test have 3.6 to 6.9-fold increased risk for
coronary events in the next 5 years.26,27 The most widely used non-invasive ischemia
test is single photon emitting CT (SPECT). Compared to SPECT, there are im-
portant advantages of APMR: superior diagnostic accuracy, lack of radiation, and
higher spatial resolution, enabling detection of subendocardial perfusion defects.5,28
Compared to FFR, APMR has an excellent diagnostic accuracy.6,29
Distinguishing the culprit stenosis leading to ischemia in patients with serial stenoses
in the culprit coronary artery can be diﬃcult. When two stenoses are present, both
aﬀect coronary ﬂow, even if individual stenoses are only moderate in severity. This
may still warrant an intervention in one or both stenoses.30 This was the reason that
we measured CCO decrease across the stenosis as well as across the entire vessel,




Our study has limitations. Firstly compared to the CCO method in literature,12 we
propose a slightly altered approach, based on semi-automated HU measurements
using curved multiplanar reconstructions. We found high reproducibility and excel-
lent inter-reader agreement. Using our method, CCO assessment requires less skill
and could be faster, and thus, can be more easily applicable in clinical practice. Se-
condly, a low number of patients had inducible ischemia on APMR. The calculated
power shows that the sample size was large enough to ﬁnd signiﬁcant associations.
Although the outcome rate was low, signiﬁcant relationships were already found be-
tween CCO decrease and myocardial ischemia. Finally, only cardiac asymptomatic
subjects were included in our study. Studies in symptomatic populations should con-
ﬁrm our ﬁndings.
Figure 4.6: Receiver-Operator-Characteristic (ROC) curve. Solid line represents vessel-based
analysis. AUC was 0.79 (0.68-0.91)
















In conclusion, decrease in CCO across coronary stenosis is associated with myocar-
dial ischemia on APMR. CCO based on common cCTA data is a novel method to
assess functional signiﬁcance of anatomical stenosis. Mere anatomical stenosis did
not cause a diﬀerence in CCO decrease. The CCO may oﬀer a rather simple and
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straightforward measurement to evaluate the hemodynamic signiﬁcance of stenosis
on cCTA without additional radiation dose. CCO can potentially exclude the majority
of hemodynamically insigniﬁcant coronary stenoses from further workup. Studies in
larger patient populations should assess whether CCO calculation may obviate the
need for ischemia testing, and derive CCO cut-oﬀ points to distinguish normal versus
reduced coronary ﬂow.
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Relationship between epicardial adipose
tissue and subclinical coronary artery
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Objectives Epicardial adipose tissue (EAT) and mediastinal adipose tissue (MAT)
are linked to coronary artery disease (CAD). The association between EAT, MAT
and severity of CAD in known extra-cardiac arterial disease was investigated.
Methods Sixty-ﬁve cardiac asymptomatic patients (mean age 65 ± 8 years, 69 %
male) with peripheral arterial disease, carotid stenosis, or aortic aneurysm under-
went coronary computed tomography angiography. Patients were divided into non-
signiﬁcant (<50 % stenosis, n = 35), single vessel (n = 15) and multi-vessel CAD
(n = 15). EAT and MAT were quantiﬁed on computed tomography images using
volumetric software.
Results Subgroups did not signiﬁcantly diﬀer by age, gender, or cardiovascular risk
factors. Median EAT was 99.5, 98.0, and 112.0 cm3 (P = 0.38) and median MAT
was 66.0, 90.0, and 81.0 cm3 (P = 0.53) for non-signiﬁcant, single vessel, and
multi-vessel CAD, respectively. In age- and gender-adjusted analysis, only EAT was
signiﬁcantly associated with CAD (odds ratio [OR] 1.12 [95 % conﬁdence interval,
1.01-1.25] per 10 cm3 increase in EAT; P = 0.04). This remained in multivariate-
adjusted analysis (OR 1.21 [1.04-1.39]; P = 0.01).
Conclusion In patients with known extra-cardiac arterial disease, CAD is correlated
with EAT, but not with MAT. These results suggest that EAT has a local eﬀect on
coronary atherosclerosis, apart from the endocrine eﬀect of visceral fat.
Published in Obesity




Visceral adipose tissue deposits have been found to exert various eﬀects.1 Mesenteric
and thoracic adipose tissue, one of the largest deposits of visceral adipose tissue, has
been associated with atherosclerosis markers.2 Epicardial adipose tissue (EAT), like
visceral adipose tissue, is metabolically active and produces hormones, although its
exact function is still unclear. EAT covers about 80 % of the heart, and surrounds
the epicardial coronary arteries and is assumed to play a role in the pathogenesis
of coronary artery disease (CAD).3–5 Possibly there is an additional, direct eﬀect
of EAT on the development of coronary atherosclerosis, on top of the endocrine
eﬀect of diﬀerent visceral fat deposits. However, this has yet to be conﬁrmed.
Mediastinal adipose tissue (MAT) is separated from the heart by the pericardium.
It is more closely related to cardiovascular risk factors than EAT. However, EAT
demonstrates a stronger association with vascular calciﬁcations, possibly due to the
paracrine eﬀects.6
First attempts to visualize and quantify EAT thickness were performed by echo-
cardiography, however, echocardiography does not yield an adequate window of all
cardiac segments.7 Furthermore, it depends on acoustic windows, which can make it
inadequate to assess obese patients.8 With more recent developments in computed
tomography (CT) and magnetic resonance imaging (MRI), accurate volumetric mea-
surements of EAT have become possible.9 CT has a high temporal and spatial reso-
lution with submillimeter collimation, and provides a three-dimensional view of the
heart and epicardial surface.10 MRI, on the other hand, is somewhat limited in spatial
resolution.
Several studies have demonstrated an association between EAT volume and the pres-
ence of obstructive CAD.11–16 These studies were performed in low to intermediate
risk patients without known atherosclerotic disease. Whether the eﬀect of adipose
tissue on the coronary arteries is due to local or endocrine eﬀects cannot be teased
out as there is a correlation between epicardial adipose tissue and other visceral adi-
pose tissue deposits. In a homogenous group of patients with known vascular disease,
it is assumed that the endocrine eﬀect of visceral adipose tissue on the vessel wall
is relatively similar and accounted for. This oﬀers the possibility to examine the
potential, additional local eﬀect of EAT on CAD.
The aim of this study is to examine the relationship between EAT, MAT, and the
prevalence of CAD in patients with extra-cardiac arterial disease.
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5.2 Materials and Methods
Patients
The current investigation was performed as a sub study of the GROUND2 study.17
In this study, cardiac asymptomatic patients with a history of extra-cardiac arterial
disease (intermittent claudication, carotid stenosis or abdominal aortic aneurysm)
underwent non-invasive cardiac imaging by CT and MRI. The study protocol was
approved by the internal institutional review board of the University Medical Center
Groningen. In the current study sixty-ﬁve patients, who had undergone coronary CT
angiography (cCTA) performed at our institution, were included.
The following risk factors for cardiovascular disease were assessed and measured:
smoking, overweight (deﬁned as a body mass index >25 kg/m2), diabetes mellitus,
hypertension (deﬁned as as systolic blood pressure ≥140 mmHg and/or diastolic
blood pressure≥90 mmHg or current anti-hypertensive medication) and dyslipidaemia
(deﬁned as low density lipoprotein of more than 4.0 mmol/l, high density lipoprotein
of less than 1.2 mmol/l for women or 1.0 mmol/l for men, or triglycerides of over
4.0 mmol/l or current cholesterol-lowering therapy).
Computed tomography
All CT scans were performed on a dual-source CT scanner (SOMATOM Deﬁnition,
Siemens, Erlangen, Germany) using a standard scanning protocol.
CCTA was performed in spiral mode, using retrospective electrocardiographic gating.
Scanning parameters were as follows: 32 × 0.6 mm collimation, image acquisition
64 × 2 × 0.6 mm with ﬂying z-spot, increment 0.4 mm, 330 ms rotation time, tube
voltage and tube current according to weight, pitch depending on heart rate of the
patient, ﬁeld-of-view 205 mm. Images were reconstructed as consecutive 0.6 mm
slices.
Assessment of coronary artery disease
Analysis of the cCTA was performed by the attending radiologist, with experience in
cardiac CT ranging from 5 to over 10 years. Syngo (Siemens, Erlangen, Germany)
was used for coronary evaluation. In the 15-segment modiﬁed AHA classiﬁcation,18
all segments were evaluated independently of image quality. Segments were classiﬁed
as having signiﬁcant stenosis when there was ≥50 % lumen diameter reduction by
visual assessment.
Patients were classiﬁed as having no signiﬁcant CAD, signiﬁcant CAD in a single
vessel, or signiﬁcant CAD in multiple vessels.
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Measurement of EAT and MAT
EAT and MAT were quantiﬁed as total volume (cm3) using dedicated software
(Aquarius iNtuition, TeraRecon, San Mateo, USA) based on the cCTA reconstruc-
tions. The superior border for EAT and MAT was deﬁned as the center of the
right pulmonary artery, the inferior border was the caudal border of the pericardial
sac. EAT, deﬁned as adipose tissue within the visceral layer of the pericardium, was
measured by manually tracing the pericardium. The anterior border for MAT was
deﬁned as the sternum, the posterior border as the front of the vertebral column.
Hounsﬁeld units from -195 to -45 were used to isolate adipose tissue within the total
selected volume. Adipose tissue was then automatically quantiﬁed by the software.
To calculate the MAT, EAT was subtracted from the total selected adipose tissue.
Figure 5.1 shows an example of EAT and MAT. In additional analysis, EAT and MAT
measurements were divided by body surface area to correct for subcutaneous adipose
tissue.
Figure 5.1: Example of measurements of thoracic adipose tissue, showing epicardial adipose
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Statistical analysis
Continuous values are presented as mean with standard deviation for normally dis-
tributed variables and median with 25th/75th percentile for non-normally distributed
variables. For dichotomous variables, percentages are given. To investigate diﬀer-
ences between the groups, a t-test was applied for normally distributed, continuous
variables, a Kruskal-Wallis test for continuous variables with non-normal distribu-
tion, and Chi-square test for categorical variables. The Jonckheere-Terpstra test
was used to investigate the trend between extent of coronary atherosclerosis in the
three groups and the amount of fat.
Spearman correlation analyses were performed to examine the relationship between
cardiovascular risk factors and EAT as well as MAT, and between diﬀerent adipose
tissue measurements. Then, multinomial logistic regression analyses were performed
to assess the association between EAT volume, MAT volume and levels of CAD
independent of confounding factors. For this, two models were created. The ﬁrst
model corrected for age and gender.
The second model corrected for all cardiovascular risk factors, including body mass
index. The odds ratio with the 95 % conﬁdence interval (CI) of EAT and MAT
volume was calculated for each 10 cm3 increase in volume. The statistical analyses
for EAT and MAT adjusted for body surface area were repeated. In the logistic
regression analyses, body mass index was removed from the second model.
All statistical analyses were performed using PASW Statistics version 19.0.0.1 (SPSS
Inc, Chicago, USA). All statistical tests were two-sided, and a P -value of <0.05 was
considered to be statistically signiﬁcant.
5.3 Results
Patient characteristics are shown in Table 5.1. CCTA was successfully performed,
and of good diagnostic quality for coronary evaluation in all 65 patients. The majority
of the patients were male (69 %). Mean age was 65 years, 53 % of patients were
overweight. Non-signiﬁcant, single vessel and multi-vessel disease on cCTA was
present in 54, 23 and 23 %, respectively. EAT ranged from 47.5 to 288.0 cm3, with
a median of 100.0 (25th, 75th percentile 82.3, 133.0). Amount of MAT ranged from
17.4 to 453.0 cm3; median was 77.0 (51.1, 109.5). Median EAT was 99.5, 98.0 and
112.0 cm3 (P = 0.38) and median MAT was 66.0, 90.0 and 81.0 cm3 (P = 0.53) for
the 3 groups, respectively. Most cardiovascular risk factors were correlated with the
amount of EAT and MAT (see Table 5.2), except for male gender in case of EAT,
and except for blood pressure and hypertension in case of MAT.
Figure 5.2 and 5.3 show box plots of the distribution of EAT and MAT, respectively,
by level of CAD. There was a tendency towards a higher median EAT in patients
with multivessel CAD compared to non-signiﬁcant and single vessel CAD, although
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Age (years) 64 ± 8 66 ± 7 67 ± 8 0.57
Male gender (%) 62.9 73.3 80.0 0.45
Body mass index (kg/m2) 26.0 ± 4.6 25.8 ± 2.4 26.7 ± 4.0 0.82
Systolic BP (mm Hg) 145 ± 23 138 ± 19 137 ± 22 0.46
Diastolic BP (mm Hg) 79 ± 9 81 ± 11 78 ± 8 0.70
Hypertension (%) 80.0 73.3 100 0.12








HDL (mmol/l) 1.1 (0.8, 1.6) 1.1 (0.9, 1.4) 1.3 (1.0, 1.5) 0.77
LDL (mmol/l) 2.7 (2.1, 3.5) 3.0 (2.2, 3.9) 2.5 (2.2, 3.3) 0.70
Dyslipidemia (%) 97.1 93.3 80.0 0.11
Glucose (mmol/l) 5.7 (5.9, 6.0) 5.2 (5.1, 5.9) 5.7 (5.2, 6.4) 0.35
Diabetes mellitus (%) 22.9 20.0 40.0 0.37
Smoking (%) 37.1 33.3 20.0 0.49
Extra-cardiac arterial disease 0.05
Intermittent claudication (%) 48.6 60.0 80.0
Carotid stenosis (%) 25.7 0.0 13.3
AAA (%) 25.7 40.0 6.7
Continuous variables are expressed as mean ± SD or median (25th, 75th percentile), di-
chotomous variables are expressed as percentages. CAD Coronary artery disease BP blood
pressure HDL high density lipoprotein LDL low density lipoprotein AAA Abdominal Aortic
Aneurysm
this tendency did not reach statistical signiﬁcance. In patients with single vessel
CAD, median EAT was not higher compared to patients with non-signiﬁcant CAD.
For median MAT, no tendency of increasing fat measures was visible with increasing
severity of CAD.
Table 5.3 outlines the odds ratios with 95 % conﬁdence intervals in the diﬀerent
logistic regression models. In age- and gender-adjusted analysis, EAT was signiﬁ-
cantly associated with CAD (Odds ratio per 10 cm3 increase in EAT = 1.12, 95 %
CI = 1.01-1.25, P = 0.04). When we corrected for all cardiovascular risk factors,
this relationship remained signiﬁcant (OR = 1.21, 95 % CI = 1.04-1.39, P = 0.01).
There was no association between increase in MAT and probability of increasing level
of CAD, not even when corrected for risk factors.
EAT adjusted for body surface area ranged from 27.4 to 141.9 cm3/m2, with a
median of 54.3 (43.9, 70.2). MAT adjusted for body surface area ranged from 9.7
to 202.6, with a median of 39.4 (27.3, 53.6). EAT adjusted for body surface area was
strongly correlated with EAT (r = 0.944, P <0.001). MAT adjusted for body surface
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Table 5.2: Univariate correlation analysis between cardiovascular risk factors and thoracic fat
measurements
EAT MAT
Spearman r P -value Spearman r P -value
Male gender 0.05 0.69 0.27 0.03
Systolic BP -0.27 0.04 -0.16 0.22
Diastolic BP -0.29 0.03 -0.06 0.65
HDL-cholesterol -0.45 <0.001 -0.45 <0.001
Tryglycerides 0.51 <0.001 0.39 0.002
BMI 0.44 <0.001 0.55 <0.001
Overweight 0.48 <0.001 0.50 <0.001
Hypertension -0.25 <0.001 0.07 0.57
EAT Epicardial adipose tissue MAT mediastinal adipose tissue BP blood pressure HDL
high density lipoprotein BMI body mass index
area was also highly correlated with MAT (r = 0.975, P <0.001). The association
between EAT adjusted for body surface area and CAD was signiﬁcant only when we
corrected for all cardiovascular risk factors (OR per 10 cm3/m2 increase in adjusted
EAT = 1.41, 95 % CI = 1.08-1.84, P = 0.01). MAT adjusted for body surface area
was not signiﬁcantly correlated with CAD, not even when corrected for risk factors.
5.4 Discussion
In patients with extra-cardiac arterial disease, a signiﬁcant, although moderate, as-
sociation between EAT and CAD was demonstrated. This association persisted after
correction for traditional risk factors, and was still present when EAT was adjusted
for body surface area. No such association was present for MAT or MAT adjusted for
body surface area, as measures of purely endocrine-acting visceral fat. The fact that
an association was found for EAT but not for MAT supports our hypothesis of a local,
direct interaction of EAT with the coronary arteries through paracrine or vasocrine
pathways, in contrast to the more endocrine eﬀect of MAT that is likely already
accounted for due to the speciﬁc study population, with symptomatic atherosclerosis
elsewhere.
The strength of the relationship between EAT and CAD in our study was only mode-
rate compared to the strength reported in other studies. A possible explanation for
this could be that patients with extra-cardiac arterial disease already have higher val-
ues of EAT and MAT compared to patients with suspected CAD but without known
atherosclerotic disease. In other studies, the volume of EAT in patients without coro-
nary artery disease was indeed lower compared to our study population.19–23 Only
patients with a high clinical suspicion of CAD or demonstrated CAD had a higher
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Table 5.3: Odds ratios for increasing levels of coronary artery disease by 10 cm3 increase in
fat measurements
Model 1 Model 2
Odds ratio
(95 % CI)
P -value Odds ratio
(95 % CI)
P -value
EAT ( per 10 cm3) 1.12 (1.01-1.25) 0.04 1.21 (1.04-1.39) 0.01
MAT (per 10 cm3) 0.93 (0.85-1.01) 0.09 0.88 (0.77-1.01) 0.07
Adj. EAT (per 10 cm3/m2) 1.25 (1.00-1.56) 0.05 1.41 (1.08-1.84) 0.01
Adj. MAT (per 10 cm3/m2) 0.87 (0.72-1.06) 0.17 0.81 (0.63-1.02) 0.07
CI Conﬁdence interval EAT epicardial adipose tissue MAT mediastinal adipose tissue BP
blood pressure HDL high density lipoprotein BMI body mass index Model 1 was corrected
for age and gender. Model 2 was corrected for all cardiovascular risk factors (age, gender,
body mass index, hypertension, dyslipidemia, diabetes mellitus and smoking). Adjusted EAT
is deﬁned as EAT divided by body surface area. Adjusted MAT as MAT divided by body
surface area
epicardial adipose tissue volume.12,13,24 On a positive note, since extra-cardiac arte-
rial disease, as expression of a generalized, endocrine eﬀect of visceral adipose tissue,
was present in all study subjects, this allowed us to tease out the local, additional
eﬀect of EAT on coronary atherosclerosis. In contrast to EAT, there is no agreed
deﬁnition on the measurement of MAT. Therefore, it is not possible to compare the
MAT volume of our population to values in the literature.
Other studies have shown a correlation with EAT and CAD in diﬀerent study popula-
tions. Ueno et al.14 demonstrated a signiﬁcant correlation with adjusted EAT and the
severity of CAD. Furthermore, they concluded that adjusted EAT was higher in pa-
tients with a history of acute coronary syndrome and coronary occlusions. Iwasaki et
al.13 reported a relationship between EAT and signiﬁcant coronary stenosis on invasive
coronary angiography. A study among 112 patients suspected for CAD, but without
known history of CAD showed a relationship between adjusted EAT and ischemia on
positron-emission tomography (PET)/CT.25 Several studies have demonstrated that
EAT is independently associated with the coronary calcium score,20,21,26,27 although
other studies did not show any relationship between EAT and calcium score27 unless
patients had a low body mass index.24 Studies have also shown a correlation between
MAT and cardiovascular risk factors.6,28
EAT can be measured as total volume or as thickness, usually on the right ventri-
cular free wall. Gorter et al.29 found a good correlation between both fat area and
thickness. They concluded that thickness is an easier and faster way to measure
EAT, but volume measurement is a more reproducible method. Other studies have
conﬁrmed that volumetric EAT measurement is highly reproducible, even with the
use of diﬀerent CT scanner generations.12,30 In this study, the contrast-enhanced
cCTA was used for the measurement of adipose tissue. It is also possible to measure
EAT on the non-enhanced scan used for coronary calcium scoring, which is advanta-
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geous in way of less radiation and no need for iodine contrast injection. This would
be more acceptable for assessment of adipose tissue as a risk factor and has already
been used in literature.11,30 However, coronary stenosis as sign of signiﬁcant CAD
can not be determined on a non-enhanced CT scan. It is not known how the results
of fat measurements based on contrast- and non-contrast-enhanced scans correlate.
Future research on this issue is needed.
Figure 5.2: Boxplot of median epicardial adipose tissue at diﬀerent levels of coronary artery
disease (CAD). Epicardial adipose tissue volume is higher, although not signiﬁcantly, in pa-
tients with multivessel CAD
P = 0.48
 95 % CI = -34.0 - 19.9
P = 0.68
 95 % CI = -35.7 - 31.0
P = 0.94
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There are several eﬀects thought to be associated with EAT. EAT produces pro-
inﬂammatory and pro-atherogenic cytokines, interleukins, chemokines and tumor
necrosis factors, which can locally induce atherosclerosis.10,31 On top of these para-
crine eﬀects, there are endocrine eﬀects of visceral adipose tissue, leading to hy-
pertension and insulin resistance.32 Moreover, adipose tissue can cause compression
on the ventricles, leading to diastolic dysfunction.33 Possible local protective eﬀects
are absorption of free fatty acids, protecting the myocardium, or buﬀering the coro-
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nary arteries from torsion induced by the arterial pulse wave.3 Another role might
be a temporary extra source of energy for the myocardium or protection against
hypothermia.31 Furthermore, EAT has paracrine eﬀects, such as production of anti-
inﬂammatory and anti-atherogenic adipokines.10,31 The balance between protective
and damaging eﬀects is still unknown.34,35 The exact biomechanical eﬀects of MAT
are unknown, however, it is clear that there can be no direct inﬂuence on the coronary
arteries such as the one that could be possible with EAT due to its proximity to the
coronary arteries.4
Figure 5.3: Boxplot of median mediastinal adipose tissue at diﬀerent levels of coronary artery
disease (CAD). No increase in mediastinal adipose tissue volume in patients with increasing
severity of CAD was present
P = 0.48
 95 % CI = -34.0 - 19.9
P = 0.68
 95 % CI = -35.7 - 31.0
P = 0.94
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This study has strengths and limitations. As a major advantage, a very speciﬁc
population of patients with vascular disease was included. In these patients, it is
assumed that the endocrine eﬀect of visceral fat on the vessel wall is relatively similar
and already taken into account. This enables to investigate a potential additional,
direct eﬀect of EAT on the severity of CAD. It is not exactly known if and how this
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can be translated to a more general population. Intra-abdominal visceral adipose
tissue or waist circumference was not measured for comparison with EAT and MAT.
Although this visceral fat depot is described to have similar eﬀects as EAT, it was
outside of the CT scan range. We used MAT as measure of endocrine-acting visceral
fat as this could be calculated on the same scan. As all patients included in the study
have symptomatic peripheral vascular disease, the prevalence of cardiovascular risk
factors is high. The degree of subclinical CAD was not known before the cCTA,
which was performed as part of this study. We did not ﬁnd statistically signiﬁcant
diﬀerences in the prevalence of cardiovascular risk factors, as assessed at baseline, by
CAD group. We assume that the percentages varied among the three CAD groups is
mostly due to chance. As the current study reports the baseline risk factor levels and
cCTA results, prior to any potential change in therapy based on cCTA results, we
consider the possibility of confounding by indication unlikely. To limit the possibility
of bias in our study, the radiologists who read the cCTA scans had no knowledge of
the risk factors or vascular treatment (invasive or pharmacological) of the scanned
participants. The study participant was referred to a cardiologist in case of a left
main stenosis or equivalent on cCTA. Potential additional work-up or treatment due
to the severity of subclinical CAD, as evident from the cCTA scans, was left at the
discretion of the cardiologist. The current study was likely underpowered due to
the relatively small cohort of patients. This is mainly caused by the fact that many
patients with extra-cardiac arterial disease already have symptomatic CAD for which
they are treated. In these patients, there is currently no accepted role for cCTA in the
assessment of the extent of CAD.36 This exclusion criterion of the GROUND2 study
considerably restricted the pool of eligible patients. Thus, the ﬁndings in the current
study should be considered preliminary ﬁndings. Nevertheless, we found a clear,
statistically signiﬁcant association between the amount of EAT and the severity of
subclinical CAD. This relationship merits further study in larger patient populations.
In conclusion, there was a positive but moderate association between epicardial adi-
pose tissue and the presence of CAD in patients with known extra-cardiac athero-
sclerosis. This association persisted when EAT was adjusted for body surface area.
No such relationship was present for mediastinal adipose tissue. The results suggest
that there could be a local, direct eﬀect of EAT on coronary atherosclerosis, apart
from the endocrine eﬀect of visceral adipose tissue. Although our study was likely
underpowered, we found a signiﬁcant association between EAT and degree of subcli-
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Objectives Advanced glycation endproducts (AGEs) may be involved in the develop-
ment of atherosclerosis, beyond diabetes and renal disease. Skin autoﬂuorescence
(AF) is a non-invasive marker for AGEs. We examined whether skin AF is increased
in (subclinical) atherosclerosis and associated with the degree of atherosclerosis in-
dependent of diabetes and renal function.
Methods A cross-sectional study of 223 patients referred for primary (n = 163) or
secondary (n = 60) prevention between 2006 and 2012 was performed. Skin AF
was measured using the AGE-Reader. Ultrasonography was used to assess plaques
in carotid and femoral arteries and computed tomography for the calculation of
the coronary artery calcium score (in primary prevention only). Primary prevention
patients were divided into a group with subclinical atherosclerosis deﬁned as >1
plaque or calcium score >100 (n = 67; age 53 years [interquartile range 48-56]; 49 %
male) and without (controls; n = 96; 43 [38-51]; 55 %). Secondary prevention were
patients with extra-cardiac arterial disease (n = 60; 64 [58-70]; 73 %).
Results Skin AF was higher in subclinical and clinical atherosclerosis compared with
controls (skin AF 2.11 [interquartile range 1.83-2.46] and 2.71 [2.15-3.27] vs. 1.87
[1.68-2.12] respectively; P = 0.0005 and <0.001). In a multivariate analysis, the
association of skin AF with the atherosclerosis categories was independent of age,
sex, diabetes, presence of the metabolic syndrome, Framingham Risk Score, and renal
function. Skin AF correlated with most cardiovascular risk factors, Framingham risk
score, and IMT and calcium score.
Conclusion Skin AF is increased in documented subclinical and clinical atheroscle-
rosis, independent of known risk factors such as diabetes and renal disease. These
data suggest that AGEs may be associated with the burden of atherosclerosis and
warrant a prospective study to investigate its clinical usability as a risk assessment
tool for primary prevention.
Published in PLoS ONE




Atherosclerosis is characterized by chronic low grade inﬂammation and oxidative
stress leading to plaque formation and ultimately calciﬁcation.1 While formerly only
implicated in diabetes and renal disease, evidence for an important role of advanced
glycation endproducts (AGEs) in cardiovascular disease (CVD) beyond these condi-
tions is growing.2 AGEs are formed by non-enzymatic glycation and oxidative reac-
tions leading to stable structures accumulating on long-lived proteins. They promote
cellular stress responses by engagement of the receptor for AGEs (RAGE). AGE epi-
topes have been detected in human plaques.3 Lowering AGEs or blocking RAGE in
murine models has been found to attenuate plaque formation, supporting the involve-
ment of AGEs in atherosclerosis.3,4
Measurement of tissue AGEs may be preferable over plasma measurement, since
long-lived proteins accumulate in the tissues in which chronic complications develop.5
Thus, blood and urine AGEs do not necessarily reﬂect their tissue levels.6 We deve-
loped and validated a non-invasive technique to quantify tissue AGEs by measuring
skin autoﬂuorescence (AF).7,8 It has been validated with skin biopsies in patients
with diabetes or renal disease and healthy controls7–9 and was shown to correlate
strongly with plasma circulating AGEs and with corneal and lens ﬂuorescence in type 1
diabetes.10 Skin AF is elevated in diabetes mellitus and end-stage renal disease and is
associated with cardiovascular mortality, independent of known CVD risk factors.8,11
Skin AF is also elevated in coronary artery disease,12,13 correlates with carotid intima
media thickness (IMT),14 and is elevated in patients with carotid artery stenosis and
extra-cardiac artery disease (ECAD),15,16 irrespective of diabetes or renal disease.
Atherosclerosis is a generalized disease that develops years before clinical events oc-
cur. Previous studies have only focused on symptomatic disease in a single vascular
bed (coronary, carotid, or femoral). It is yet unclear whether skin AF is already in-
creased in subjects with subclinical atherosclerosis. We hypothesized that skin AF
is increased in patients with subclinical atherosclerosis, independent of diabetes and
renal function, and that skin AF is positively associated with the degree of athero-
sclerosis. Therefore, we compared skin AF in subjects without and with subclinical
atherosclerosis as ascertained by non-invasive imaging measures, and in patients with
clinically overt and established atherosclerosis.
6.2 Materials and Methods
Patients
We performed a cross-sectional study of 223 patients, at least 18 years of age, visi-
ting the outpatient vascular clinic of our hospital for primary (n = 163) or secondary
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(n = 60) cardiovascular prevention between 2006 and 2012. The study was approved
by the local institutional review board at the University Medical Center Groningen and
all participants gave written informed consent. Eligible patients of the primary pre-
vention group were referred for counselling because of an increased CVD risk based
on conventional cardiovascular risk factors and did not have a history of CVD or
symptoms of coronary artery disease, cerebrovascular disease or ECAD. The primary
prevention group was divided in patients with and without evidence of subclinical
atherosclerosis, the latter forming the control group. Subclinical atherosclerosis was
deﬁned as the presence of one or more plaques in carotid and femoral arteries using
high resolution ultrasonography or a coronary artery calcium score >100 on computed
tomography (CT). These cut-oﬀs were chosen on the basis of previous reports show-
ing that subjects meeting these criteria are at substantially increased CVD risk.17,18
The secondary prevention group consisted of patients with proven ECAD, which was
ascertained by a resting ankle-brachial index ≤0.90 or a toe-brachial index ≤0.70
if possible in case of non-compressible calf arteries, or a history of radiological or
surgical intervention for ECAD. ECAD was conﬁrmed by CT angiography, magnetic
resonance angiography or catheter angiography. For both primary and secondary
prevention, exclusion criteria consisted of an estimated glomerular ﬁltration rate of
<60 ml/min/1.73 m2, a history of renal transplantation, a recent acute coronary syn-
drome or cerebrovascular attack, or sepsis (all within the past 3 months), cognitive
impairment, or current cancer or autoimmune disease because these conditions have
previously been shown to increase skin AF. Furthermore, those with a brown or black
skin (Fitzpatrick type V skin) were excluded because skin AF could not be reliably
measured with the device used in the current study due to excessive light absorp-
tion in this skin type. In the primary and secondary prevention group, skin AF and
calcium score measurements were performed. Since the secondary prevention group
of ECAD patients by deﬁnition had clinically established and proven atherosclerotic
disease, no ultrasonographic plaque scoring was performed in this group.
Risk factor assessment
The following risk factors were assessed: smoking status, dyslipidaemia (fasting low
density lipoprotein (LDL) cholesterol >4.0 mmol/l, high density lipoprotein (HDL)
cholesterol <1.2 mmol/l (female) or HDL-cholesterol <1.0 mmol/l (male), triglyce-
rides >4.0 mmol/l, or current lipid lowering treatment), hypertension (blood pressure
≥140/90 mmHg or drug treatment for hypertension), obesity (body mass index
(BMI) ≥30 kg/m2), family history of premature CVD (in ﬁrst degree relatives, male
<55 years and female <65 years), and diabetes mellitus (known diabetes, fasting
plasma glucose >7.0 mmol/l or random plasma glucose >11.1 mmol/l). Medication
use was documented and additional measurements of serum creatinine and high-
sensitive C-reactive protein (hsCRP) were performed. Metabolic syndrome was de-
ﬁned according to the International Diabetes Federation, in which BMI substituted
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waist circumference, because the latter was unavailable.19 Framingham risk score
was deﬁned as the 10 year risk of coronary heart disease (i.e. myocardial infarction
or death from coronary heart disease).20 Kidney function was estimated using the
MDRD formula.21
Measurement of skin autofluorescence
Skin AF was assessed using the AGE Reader (DiagnOptics Technologies BV, Gronin-
gen, the Netherlands). This is a non-invasive desk-top device that uses the charac-
teristic ﬂuorescent properties of certain AGEs to estimate the level of AGEs accumu-
lation in the skin. The method has been extensively validated and strongly correlates
with individual AGE compounds measured in skin biopsy dermal tissue homogenates
taken from the same site as skin AF measurement.22 Technical details concerning
the optical technique have been described elsewhere.7 In short, the right forearm was
positioned on top of the device which is the standard and most practical measuring
site for skin AF. The AGE Reader illuminates a skin surface of 4 cm2 with an exci-
tation light source with a peak excitation of 370 nm. Emission light (ﬂuorescence in
the wavelength of 420-600 nm) and reﬂected excitation light (with a wavelength of
300-420 nm) from the skin is measured with a spectrometer. Skin AF is calculated
as the ratio between the emission light and reﬂected excitation light, multiplied by
100 and expressed in arbitrary units. A series of three consecutive measurements
was carried out, taking less than a minute of time. Mean skin AF was calculated
from these three consecutive measurements and used in the analyses. The method
is observer independent and has an intra-patient coeﬃcient of variation of 5 %.7
Plaque assessment by intima media thickness
Plaque assessment was performed by measurement of carotid and femoral IMT, as
described previously.23 High resolution B-mode ultrasonography (Acuson 128XP10,
Acuson Corporation, Mountainview, USA) with a 7 MHz linear array transducer was
used with the subject in a supine position. For both carotid arteries, a mean value
over 10 mm length of the far wall segments of the common and internal carotid
artery and the carotid bulb were imaged from a ﬁxed lateral transducer position.
The same procedure was used for the femoral arteries, with measurement of seg-
ments of the common femoral artery and the superﬁcial femoral artery. Mean and
maximum IMT of each of the 10 segments was calculated. Presence of a plaque
was based on the Mannheim consensus statement. A plaque is deﬁned as a focal
structure that encroaches onto the arterial lumen at least 0.5 mm or 50 % of the
surrounding IMT value or demonstrates a thickness of ≥1.5 mm as measured from
the media-adventitia interface to the intima-lumen interface.24 A total plaque score
was calculated summing all segments with presence of at least one plaque, conse-
quently ranging from 0 to 10. The sonographers were unaware of the risk factors
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of the studied persons. The measurements were analyzed oﬄine by an independent
image analyst who also was unaware of the clinical status of the patient.
Measurement of coronary calcium score
Calcium score was measured either with electron beam CT (C-150 Imatron, San
Francisco, USA) or dual-source CT (SOMATOM Deﬁnition, Siemens, Erlangen,
Germany). A standard scanning protocol was applied. The scan range was from the
carina to 1.5 cm below the base of the heart. Images were acquired at 80 % of the
cardiac cycle for electron beam CT or 70 % for dual-source CT, with electrocardio-
graphic triggering, during a single breath-hold. For electron beam CT 38 contiguous,
3 mm thick slices were obtained, with a scan time of 100 ms per slice. Tube voltage
was 120 kV, with a tube current of 64 mA and a ﬁeld-of-view of 260 mm. For
dual-source CT a sequential scanning protocol was used, with 6 × 3 mm collimation,
330 ms rotation time, tube voltage 120 kV, tube current dependent on the weight
of the patient and a ﬁeld-of-view of 250 mm. Quantiﬁcation of calcium score was
performed with the use of dedicated software (AccuImage Diagnostics Corporation,
South San Francisco, USA for electron beam CT, and Siemens Syngo, Erlangen,
Germany for dual-source CT) by trained readers, according to the method described
by Agatston.25 The calcium score of the dual-source CT was corrected to correlate
better with the values of the reference standard, electron beam CT.26
Laboratory analyses
Venous blood samples were collected into EDTA-containing tubes (1.5 mg/ml).
Plasma cholesterol and triglycerides were assayed by routine enzymatic methods
(Roche Diagnostics GmbH, Mannheim, Germany). HDL-cholesterol was measured
with a homogeneous enzymatic colorimetric test (Roche/Hitachi). HsCRP was de-
termined by nephelometry with a lower limit of 0.175 mg/l (BNII N; Dade Behring,
Marburg, Germany). Glucose was measured with an APEC glucose analyzer (APEC
Inc., Danvers, USA).
Statistical analysis
Based on previous studies in asymptomatic subjects, we expected a standard deviation
of 0.3 for skin AF and considered a mean diﬀerence of 0.2 arbitrary units (AU)
between patients with subclinical and those without subclinical atherosclerosis as
clinically relevant. With a power of 80 % and an alpha of 0.05 and under the
assumption of normality, at least 36 subjects were needed to reject the null hypothesis
of no diﬀerence in a 2-sided independent t-test.
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Normally distributed parameters are shown as mean with standard deviation, non-
normally distributed values are given as median (interquartile range) and categorical
variables are reported as number (percentage). To investigate diﬀerences between
the three risk groups, the Kruskal-Wallis test for continuous variables and the Chi-
square test for categorical variables was used. In case of a signiﬁcant diﬀerence
between the three groups, the Mann-Whitney U test was used to compare the sub-
clinical atherosclerosis group with the control group. Several ordinal logistic regres-
sion models were developed to examine the relationship between the atherosclerosis
groups and skin AF in addition to other risk factors. In the ﬁrst model, age, sex,
diabetes mellitus and renal function were entered as covariates and in the second
model, cardiovascular risk factors deﬁned in the Framingham risk score were added
to the ﬁrst model. In the third model, age, sex, renal function and metabolic syn-
drome were entered. The odds ratio of increasing level of atherosclerosis (control,
subclinical, clinical atherosclerosis) was calculated for each AU increase in skin AF.
The Spearman correlation coeﬃcient was used to examine the univariate association
between skin AF and other factors. Those with a P <0.10 were included in the linear
multiple regression model using stepwise selection of variables. All statistical analyses
were performed using PASW Statistics version 18.0.3 (SPSS Inc, Chicago, USA).




A total of 223 patients participated. Characteristics are shown in Table 6.1, 6.2
and 6.3. In the primary prevention group, 67 subjects had subclinical atheroscle-
rosis, while 96 subjects did not meet our criteria for subclinical atherosclerosis and
were assigned to the control group. Age, sex, BMI, systolic blood pressure, fasting
glucose, hsCRP, lipids, kidney function, the presence of diabetes mellitus, smok-
ing status, hypertension, and cardiovascular drug use diﬀered signiﬁcantly between
groups. Subjects of the subclinical atherosclerosis group were older, had a higher
BMI, systolic blood pressure, and fasting glucose levels as compared with the control
group. As expected from their need for secondary prevention, ECAD patients used
statins more frequently, and consequently had lower lipid levels.
Skin autofluorescence
Skin AF was signiﬁcantly higher in patients with subclinical atherosclerosis and ECAD
compared with controls, and skin AF was higher in the ECAD group compared with
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Age (years) 43.8 ± 9.5 51.8 ± 7.8 63.5 ± 7.6 <0.001⋆

















Systolic BP (mmHg) 130
(120-140)
136 (128-146) 139 (127-164) 0.005⋆
Diastolic BP (mmHg) 80 (73-90) 82 (75-90) 80 (75-85) 0.57
Fasting glucose (mmol/l) 5.2 (4.9-5.8) 5.3 (5.1-5.8) 5.5 (5.0-6.4) 0.09







Cholesterol (mmol/l) 5.7 (4.7-6.7) 6.0 (4.9-6.7) 4.3 (3.9-5.4) <0.001
LDL-cholesterol(mmol/l) 3.8 (2.9-4.7) 4.0 (3.3-4.5) 2.5 (2.1-3.2) <0.001






















Diabetes mellitus 3 (3.1) 2 (3.0) 13 (21.7) <0.001
Smoking 0.009
Yes 29 (30.2) 27 (40.3) 22 (36.7)
No 31 (32.3) 17 (25.4) 5 (8.3)
Past 36 (37.5) 23 (38.8) 33 (55.0)
Dyslipidaemia 77 (80.2) 59 (88.1) 51 (85.0) 0.39
Hypertension 43 (44.8) 41 (61.2) 52 (86.7) <0.001⋆
Metabolic syndrome 24 (25.0) 25 (37.3) 21 (35.0) 0.19
Framingham Risk Score 2.0 (0.4-4.1) 5.1 (2.5-11.7) 9.5 (3.2-18.3) <0.001⋆
⋆ P <0.05 between subclinical atherosclerosis and controls.
BP Blood pressure GFR glomerular ﬁltration rate using MDRD formula
the group with subclinical atherosclerosis (Figure 6.1). Within the control group, 40
subjects had no detectable plaques and a calcium score of 0 while 56 subjects had only
a single plaque and/or calcium score of 0-100; skin AF did not diﬀer between these
two groups (skin AF 1.93 [1.72-2.16] vs. 1.83 [1.67-2.05], P = 0.30). Within the
subclinical atherosclerosis group, 17 subjects had plaques only, 10 had an increased
calcium score only, and 40 had more than one plaque and increased calcium score.
Between these three groups, skin AF also did not diﬀer (2.14 [1.74-2.45] vs. 2.03
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[1.80-2.23] vs. 2.16 [1.85-2.55], P = 0.47). Finally, in the ECAD group, skin AF
was not signiﬁcantly diﬀerent between those with calcium score below and those with
calcium score above 100 (2.65 [2.10-3.35] vs. 2.72 [2.26-3.20], P = 0.92).


































The three models for ordinal regression analysis are outlined in Table 6.4. The
diﬀerence in skin AF between the 3 groups was independent of age, sex, diabetes,
and renal function (P = 0.009). Addition of Framingham risk score or replacement of
diabetes with metabolic syndrome in this model did not change the results (P = 0.017
and 0.009). In all models, the odds of having a higher degree of atherosclerosis were
2-fold increased per unit of skin AF. To investigate factors associated with skin AF,
univariate correlations were calculated in the entire group. Skin AF correlated with
age (r = 0.55; P <0.001), Framingham risk score (r = 0.35; P <0.001), diabetes
(r = 0.23; P <0.001), hypertension (r = 0.19; P=0.005), body mass index (r = 0.15;
P = 0.02), calcium score (r = 0.34; P <0.001) and systolic blood pressure (r = 0.14;
P = 0.04), but not with diastolic blood pressure. Skin AF also correlated with plasma
glucose (r = 0.20; P = 0.003), triglycerides (r = 0.17; P = 0.01), hsCRP (r = 0.31;
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P <0.001) and inversely with LDL (r = -0.16; P = 0.02). No correlations between
medication and skin AF were observed. In the linear multiple regression model, skin
AF was independently associated with age and plasma glucose (model: r2 = 0.29,
P <0.001; age: standardized beta 0.46, P <0.001; glucose: r = 0.19, P = 0.005).
Because of the low prevalence of diabetes, analyses were repeated after removal of
the patients with diabetes. This did not alter the results. In the primary prevention
group, skin AF also correlated with plaque score (r = 0.21; P = 0.008), mean IMT of
carotid and femoral arteries (r = 0.22; P = 0.004 and r = 0.13; P = 0.11) and max
IMT (r = 0.26; P = 0.001 and r = 0.21; P = 0.007), respectively. The correlation
with skin AF and calcium score did not reach signiﬁcance (r = 0.13; P = 0.09).
6.4 Discussion
In the current study we demonstrate that skin AF − a non-invasive marker for tissue
AGE accumulation − is elevated in subjects with evidence of subclinical athero-
sclerosis and subjects with clinical atherosclerosis. Furthermore, skin AF increases
with the degree of atherosclerosis, independently of factors known to be associated
with accumulation of AGEs, including age, sex, diabetes or metabolic syndrome,
kidney function and Framingham risk score. To the best of our knowledge, this is
the ﬁrst study to demonstrate an association of skin AF with varying degrees of
atherosclerosis. This was ascertained not only by measuring IMT, but also by plaque
assessment and calcium score, all of which are validated methods for measuring sub-
clinical atherosclerosis. Earlier, we reported that skin AF is increased and a strong
predictor of mortality in diabetes mellitus and end stage renal disease compared with
healthy controls.8,11 Other groups have conﬁrmed the association between skin AGEs
and coronary artery disease in patients with type 1 diabetes, using a diﬀerent setup,
referred to as skin intrinsic ﬂuorescence.27 The current study is in line with these ob-
servations and presents the new ﬁnding of a higher accumulation of AGEs in patients
with subclinical atherosclerosis, independent of diabetes and renal function, with the
simultaneous use of more than one technique.2
In line with the hypothesis of a role of AGEs beyond diabetes and renal disease, we
demonstrated earlier that skin AF is elevated in ECAD,15,16 coronary artery disease12
and myocardial infarction.13 Skin AF was shown to correlate with markers of subclini-
cal atherosclerosis, i.e. IMT14,28 and small artery elasticity,10 the soluble RAGE and
with markers of inﬂammation, endothelial activation, and oxidative stress in other
studies.12,13 These previous studies were all performed in populations with known
cardiovascular disease, diabetes, renal disease, or autoimmune diseases. This may
have confounded the relation between skin AF and atherosclerosis. The diseases per
se, especially autoimmune diseases, could cause increases in skin AF.29 The study by
Lutgers14 demonstrated an association between skin AF and IMT in healthy subjects
without diabetes. However, in this particular study plaques were not documented
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Statin use 38 (39.6) 31 (46.3) 46 (76.7) <0.001
Other lipid lowering
medication
8 (8.3) 7 (10.4) 3 (5.0) 0.53
ACEi / ARB use 8 (8.3) 11 (16.4) 37 (61.7) <0.001
Other antihypertensive
medication
14 (14.6) 15 (22.4) 34 (56.7) <0.001
Aspirin use 4 (4.2) 8 (11.9) 48 (80.0) <0.001
Coumarin use 0 (0.0) 1 (1.5) 8 (13.3) <0.001
ACEi Angiotensin-converting enzyme inhibitor ARB angiotensin receptor blocker
and no coronary calcium score was measured. Also, a preliminary version of the
AGE-Reader was used, which has not been developed further and was not validated
to skin biopsy.









Calcium score (AU) 0.0 (0.0-6.9) 130.0 (0.0-248.0) 389.8 (107.6-984.0)
Mean carotid IMT 0.65 (0.57-0.74) 0.83 (0.67-0.98) NA
Max carotid IMT 0.71 (0.60-0.82) 0.97 (0.80-1.11) NA
Mean femoral IMT 0.55 (0.48-0.67) 0.70 (0.53-1.05) NA
Max femoral IMT 0.60 (0.50-0.75) 0.80 (0.63-1.25) NA
AU Arbitrary units IMT intima media thickness NA not applicable
Correlations between (non-invasive) assessments for diﬀerent vascular beds i.e. IMT,
carotid and coronary plaque scores, and calcium score) is moderate, even in post-
mortem studies.30 No single method seems to adequately reﬂect overall atherosclero-
sis burden. In line, we found only a weak concordance between the presence of plaques
and calcium score, with most subjects presenting with plaques or coronary calciﬁca-
tions only. This supports our choice to study multiple vascular techniques and vascular
beds. The IMT value is strongly age dependent and a relatively weak predictor of
CVD. Therefore, we preferred to deﬁne atherosclerosis as the presence of plaques,
which is considered a more accurate surrogate for subclinical atherosclerosis31 and
a better predictor of future CVD.32 Although we used the Mannheim consensus de-
ﬁnition, some plaques may have been missed, since we only quantiﬁed plaques that
were present at the far wall and did not scan outside the designated segments.
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Calcium score is a stronger predictor of future coronary events33 and to a lesser
extent with CVD in general. Calcium score correlates strongly with histopathologic
coronary disease and that absence of calciﬁcation is highly suggestive for the absence
of CAD.17 We chose a cutoﬀ of >100 AU for subclinical atherosclerosis, since this is
considered optimal to separate asymptomatic subjects at high from those at low risk.
Since calcium score only detects the presence of a calciﬁed plaque, so-called “soft“
plaques are missed.34 Furthermore, with the techniques we used it is not possible to
discriminate “active“ or vulnerable from stable plaques. This would necessitate more
sophisticated and currently experimental techniques.
Table 6.4: Odds ratios for increasing degree of atherosclerosis (control, subclinical athero-
sclerosis, symptomatic peripheral arterial disease) by 1 unit increase of skin autoﬂuorescence
(Skin AF).
Skin AF
Odds ratio (95 % CI)
P -value
Model 1 2.11 (1.21, 3.68) 0.009
Model 2 1.99 (1.13, 3.50) 0.017
Model 3 2.13 (1.21, 3.74) 0.009
Model 1 was only corrected for age, sex, diabete mellitus and renal function. In model 2,
we corrected additionally for cardiovascular risk factors as Framingham risk score. Model 3
was corrected for age, sex, renal function and metabolic syndrome.
Skin AF is an indirect marker for AGEs in the skin, and is inﬂuenced by other skin ﬂuo-
rophores. Most AGEs are not ﬂuorescent. Nonetheless, in validation studies, skin AF
strongly and consistently correlated with ﬂuorescent as well non-ﬂuorescent AGEs,
including the major and most extensively studied AGE Nε-(carboxymethyl)lysine.35
We did not collect extra plasma samples and could therefore not assess plasma AGE
levels. The disadvantage of plasma AGEs is that they can be inﬂuenced and ﬂuctu-
ate due to several factors (i.e. smoking, nutrition, renal function) whereas skin AF
remains stable. Furthermore, plasma AGE measurement has an impaired reproduci-
bility due to a lack of uniformity in assays, and are not independently associated with
CVD.36 A restriction to measuring skin AF is that it could not be reliably measured
in persons with a dark skin with the AGE-Reader used in this study. However, with
the new set-up of the AGE-Reader it is possible to perform accurate measurements
in darker skin types, even in Asian or African populations.37
The use of cardiovascular drugs may have inﬂuenced AGE levels. Statins and aspirin
have been shown to reduce plasma levels of the soluble receptor for AGEs.38,39
Although no such evidence exists for the eﬀects on AGE levels in serum or tissue,
this cannot be excluded. If statin use would have caused mitigation of the association
between skin AF and extent of atherosclerosis (bias toward zero), then we expect
the actual relationship between skin AF and atherosclerosis to be stronger. The
majority of patients referred for secondary prevention were treated with lipid and
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blood pressure lowering drugs according to the latest guidelines, which explains the
relatively low levels of cholesterol and blood pressure in these patients.
Since this is a cross-sectional study, a direct etiological role of skin AF or AGEs in
atherosclerosis cannot be proven. Furthermore, the relationship between skin AF
and severity of atherosclerosis is confounded by the conventional cardiovascular risk
factors. Statistical correction inevitably results in interaction and overadjustment,
since these factors are strongly interrelated and age dependent. Because of the
small study population, we did not correct for all risk factors separately and chose to
cluster them in the Framingham risk score and metabolic syndrome. Skin AF should
not be considered a diagnostic marker to detect (subclinical) atherosclerosis, but as
an additional non-invasive marker for cardiovascular risk.
In conclusion, in this cross-sectional study we conﬁrm the hypothesis that skin AF,
a non-invasive marker for AGE accumulation, is elevated in subclinical atherosclero-
sis and subjects with clinical atherosclerosis. These data add further evidence that
accumulation of AGEs is linked to atherosclerosis, even at a subclinical level, inde-
pendent of age and sex and, importantly, diabetes and kidney disease. However,
before applying this method in clinical practice for primary prevention, these results
need conformation in a prospective cohort study.
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Extra-cardiac arterial disease (ECAD) is common in the Western population, with
a prevalence of 29 % in persons over 50 years. ECAD can be divided in stenotic
and aneurysmal disease. ECAD is associated with an elevated risk of coronary artery
disease (CAD). Patients with aneurysmal or stenotic ECAD may have similar risk of
coronary events. Screening for CAD before symptoms occur, has become a realistic
possibility with recent developments in computed tomography (CT) and magnetic
resonance (MR) imaging. Coronary CT angiography (cCTA) can detect coronary
stenosis, i.e. anatomical disease. Adenosine perfusion MR evaluates the eﬀect of
stenosis on perfusion of the myocardium, thus whether myocardial ischemia occurs
in stress. Non-invasive cardiac imaging of these patients, combined with a dedicated
treatment algorithm, may beneﬁcially aﬀect the prognosis in ECAD patients. In
this thesis, novel biomarkers of CAD based on non-invasive CT and MR imaging in
ECAD patients were studied. Chapter 1 is a general introduction on the background
of atherosclerosis and the detection of CAD.
With newer CT scanner generations, the accuracy of cCTA for detection of ob-
structive coronary stenosis compared to invasive coronary angiography has improved.
cCTA has a very high sensitivity for coronary stenosis. The speciﬁcity of cCTA may
be aﬀected by coronary calciﬁcation, since severe calciﬁcation limits lumen assess-
ment due to blooming artifacts. The amount of coronary calciﬁcation is quantiﬁed
in a calcium score, which is a marker of overall coronary atherosclerosis. In case of a
high calcium score (CS), cCTA can yield false positive results. In a meta-analysis in
over 5,000 patients (Chapter 2), it was found that the speciﬁcity of cCTA for signi-
ﬁcant stenosis remained high in case of severe coronary calciﬁcation with newer CT
systems of 64-MDCT and beyond. For patients with CS over 1,000, the speciﬁcity
of cCTA was 84 % (89 % in segment-based analysis), not signiﬁcantly lower than
overall speciﬁcity. The test characteristics for 16-MDCT scanners were signiﬁcantly
worse. The results suggest that for modern CT systems (at least 64-MDCT), a CS
cut-oﬀ above which cCTA should not be performed seems no longer indicated.
The exact prevalence of silent CAD is in the population of ECAD patients is un-
known. As coronary angiography, the reference standard, is an invasive procedure
with some risk of morbidity and mortality, this procedure is generally only performed
in case of strong suspicion of CAD. Chapter 3 shows the results of one of the ﬁrst
studies in ECAD patients assessing the presence of asymptomatic CAD using non-
invasive screening. In 111 ECAD patients without cardiac symptoms or history, A
high percentage of silent, severe coronary artery disease based on cCTA and adeno-
sine perfusion MR was found. Referral to a cardiologist because of severe CAD was
deemed necessary in nearly one ﬁfth of all patients, resulting in coronary intervention
in 9.0 % of all patients. The rate of CAD was not signiﬁcantly diﬀerent in patients
with stenotic compared with aneurysmal ECAD. Further studies may show screening
in these high risk patients to be beneﬁciary.
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Many anatomical coronary stenoses do not cause myocardial ischemia in stress and
thus, are not functionally relevant. Usually, multiple tests are needed to derive a ﬁnal
diagnosis of hemodynamically signiﬁcant CAD, with disadvantages in terms of patient
discomfort and costs. In view of the increased use of cCTA to assess CAD, it would be
extremely valuable if this same non-invasive test could determine the hemodynamic
signiﬁcance of the anatomical stenoses that are readily detected. In Chapter 4,
a novel method to assess the hemodynamic signiﬁcance of coronary stenoses was
evaluated, based on regular cCTA examinations, obtained in the group of ECAD
patients. Using semi-automatic software, the corrected contrast opaciﬁcation (CCO)
was calculated, estimating the eﬀect of stenosis on coronary ﬂow. Decrease in
CCO across coronary stenosis was associated with myocardial ischemia on adenosine
perfusion MR. Mere anatomical stenosis did not cause a diﬀerence in CCO decrease.
The CCO may oﬀer a rather simple and straightforward measurement to evaluate
the hemodynamic signiﬁcance of stenosis on cCTA without additional radiation dose.
CCO can potentially exclude the majority of hemodynamically insigniﬁcant coronary
stenoses from further workup. Studies in larger patient populations should assess
whether CCO calculation may obviate the need for ischemia testing, and derive CCO
cut-oﬀ points to distinguish normal versus reduced coronary ﬂow.
Quantitative risk markers may improve cardiovascular risk prediction. In Chapters
5 and 6 two of these new biomarkers have been investigated. Cardiac CT without
contrast for calcium scoring can yield additional information such as the amount of fat
surrounding the heart, called epicardial adipose tissue (EAT) and mediastinal adipose
tissue (MAT). EAT and MAT can be quantiﬁed with dedicated software. Several
studies have demonstrated an association between EAT and signiﬁcant CAD, but it
is unknown whether the eﬀect of fat tissue on the coronary arteries is due to local
or to endocrine eﬀects. In a homogenous group of patients with known vascular
disease, the endocrine eﬀect of visceral fat tissue on the vessel wall can be assumed
to be relatively similar and accounted for. In the ECAD patients there was a positive
but moderate association between EAT and the presence of CAD (Chapter 5).
This association persisted when EAT was adjusted for body surface area. No such
relationship was present for MAT. These results suggest that EAT has a local eﬀect
on coronary atherosclerosis, apart from the endocrine eﬀect of visceral fat. These
preliminary results merit further study in larger patient populations.
Finally, in Chapter 6 a novel biomarker to measure advanced glycation endproducts
with skin autoﬂuorescence (AF) was studied. Skin AF has been associated with
atherosclerosis in patients with diabetes or renal disease. It is yet unclear whether
skin AF is already increased in subjects with subclinical atherosclerosis on non-invasive
imaging. In this study in 223 individuals, the level of skin AF in individuals without
subclinical atherosclerosis was compared to levels in patients with subclinical and cli-
nically overt atherosclerosis. Skin AF was already higher in individuals with subclinical
atherosclerosis, independent of risk factors such as diabetes and renal disease. Also,
skin AF increased with the degree of atherosclerosis. This suggests that advanced
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glycation endproducts may be associated with the burden of atherosclerosis. Be-
fore applying this method in clinical practice for primary prevention, the results need
conformation in a prospective cohort study.
In this thesis, several new biomarkers for the detection of coronary atherosclerosis
were investigated. The results can guid further clinical studies and randomized con-
trolled trials. It is expected that cCTA and additional non-invasive biomarkers can
serve as a one-stop shop in the detection and screening for coronary artery disease,







Perifeer vaatlijden (ECAD) is een veelvoorkomende ziekte in de Westerse wereld, en
komt voor in 29 % van de mensen ouder dan 50 jaar. Perifeer vaatlijden kan worden
onderverdeeld in vernauwend (stenotisch) en verwijdend (aneurysmatisch) vaatlijden.
Perifeer vaatlijden geeft een verhoogde kans op coronairlijden. Zowel perifeer vaat-
lijden als coronairlijden hebben soortgelijke risicofactoren. Screenen op coronairlijden
voordat klachten optreden, is een reële mogelijkheid met de nieuwe ontwikkelingen in
computer tomograﬁe (CT) en magnetic resonance (MR) imaging. Met coronaire CT
angiograﬁe (cCTA) kunnen coronaire vernauwingen (stenosen) worden aangetoond,
als anatomische ziekte. Adenosine perfusie MR kan het eﬀect van de stenose op
de doorbloeding van de hartspier bepalen, en dus of er zuurstoftekort (ischaemie)
optreedt bij inspanning. Niet-invasieve cardiale beeldvorming in patiënten met peri-
feer vaatlijden, in combinatie met een goed toegepast speciaal behandelprogramma,
kan hun risico gunstig beïnvloeden. In dit proefschrift zijn nieuwe biomarkers voor
coronairlijden onderzocht, met behulp van niet-invasieve CT en MR onderzoeken
bij patiënten met perifeer vaatlijden. Hoofdstuk 1 is een algemene introductie,
gebaseerd op de achtergrond van atherosclerose en het opsporen van coronairlijden.
Nieuwere CT scanners hebben een verbeterde betrouwbaarheid van cCTA voor het
opsporen van coronairlijden ten opzichte van invasieve coronairangiograﬁe. cCTA
heeft een hoge sensitiviteit voor coronaire stenosen. De speciﬁciteit van cCTA kan
worden beïnvloed door coronaire verkalkingen, aangezien ernstige verkalkingen in de
vaatwand van de coronair de beoordeling van het bloedvat kan belemmeren door
‘blooming artefacten’, waarbij de stenose overschat wordt. De hoeveelheid kalk in
een coronair kan worden gemeten met de calcium score, die een maat is voor totale
coronaire atherosclerose. In het geval van een hoge calcium score (CS) kan cCTA
fout-positieve resultaten geven. In een meta-analyse van meer dan 5,000 patiënten
(Hoofdstuk 2) is aangetoond dat de speciﬁciteit van cCTA voor signiﬁcante stenosen
hoog bleef in het geval van ernstig coronair kalk bij gebruik van 64-detectorrijen of
meer. Bij patiënten met een CS van meer dan 1,000 was de speciﬁciteit van cCTA
84 % (89 % op segment-basis) niet signiﬁcant lager dan de totale speciﬁciteit. De
testresultaten voor 16-detectorrijen waren wel signiﬁcant slechter. Deze resultaten
suggereren dat er voor de moderne CT scanners (ten minste 64-detectorrijen) geen
afkapwaarde voor de CS meer nodig is.
De exacte prevalentie van stil coronairlijden (patiënten hebben geen bijbehorende
klachten) bij patiënten met perifeer vaatlijden is nog niet bekend. Coronairan-
giograﬁe, de gouden standaard, is een invasieve procedure met een klein risico op
morbiditeit en sterfte. Deze procedure is over het algemeen alleen toegepast bij
patiënten met een sterke verdenking op coronairlijden. In Hoofdstuk 3 worden de
resultaten beschreven van een van de eerste studies waarin de aanwezigheid van stil
coronairlijden onderzocht werd bij patiënten met perifeer vaatlijden, met behulp van
niet-invasieve screening. Bij 111 patiënten met perifeer vaatlijden, zonder cardiale
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klachten, is een hoge prevalentie van stil, ernstig coronairlijden gevonden met behulp
van cCTA en adenosine perfusie MR. Ongeveer een vijfde deel van alle patiënten
werd naar de cardioloog verwezen voor ernstig coronairlijden, met als resultaat dat
bij 9 % van alle patiënten een interventie geïndiceerd was. Er was geen verschil
in aanwezigheid van coronairlijden voor patiënten met stenotisch of aneurysmatisch
vaatlijden. Vervolgstudies zijn nodig om de mogelijke voordelen van screening in deze
hoog-risico patiëntengroep te bevestigen.
Veel anatomische stenosen veroorzaken geen zuurstoftekort in de hartspier en zijn
dus niet functioneel relevant. Gewoonlijk zijn er meerdere onderzoeken nodig om
een deﬁnitieve diagnose van functioneel relevante of haemodynamisch relevante co-
ronairlijden vast te stellen, met de nadelen van extra patiëntbelasting en de kosten.
Met het toenemende gebruik van cCTA voor het opsporen van coronairlijden zou het
zeer waardevol zijn als dit niet-invasief onderzoek ook de functionele relevantie van
eerder aangetoonde anatomische stenosen in beeld zou kunnen brengen. In Hoofd-
stuk 4 is een nieuwe methode onderzocht om de haemodynamische signiﬁcantie van
coronaire stenosen te beoordelen, via de normale cCTA onderzoeken, bij patiënten
met perifeer vaatlijden. Met semi-automatische software werd de gecorrigeerde con-
trastopaciﬁcatie (CCO) berekend, als voorspelling van het eﬀect van een stenose op
de bloedstroom in de coronair. Contrastopaciﬁcatie is een maat voor de aankleuring
van bloedvat door de hoeveelheid contrastmiddel. Een hogere contrastopaciﬁcatie
betekent meer contrastmiddel dat door het bloedvat stroomt. Een afname in de
CCO over een coronaire stenose was geassocieerd met zuurstoftekort bij adenosine
perfusie MR. Simpele anatomische stenosen zonder functionele relevantie gaven geen
CCO afname. CCO kan een eenvoudige meting zijn om de functionele relevantie van
een stenose op cCTA te beoordelen, zonder aanvullende straling. CCO kan mogelijk
het grootste deel van de haemodynamisch niet-signiﬁcante stenosen uit te sluiten
van verder vervolgonderzoek. Wel zijn er nog studies nodig met grotere groepen
patiënten om een afkapwaarde van CCO te bepalen. In de toekomst is het mogelijk
om met een enkel onderzoek onderscheid te maken tussen normale en verminderde
coronaire doorbloeding.
Nieuwe risico-markers kunnen de voorspelling van het cardiovasculaire risico ver-
beteren. Daarom zijn in Hoofdstuk 5 en 6 twee van de deze nieuwe biomarkers
onderzocht. Een blanco CT coronairen kan worden gebruikt voor de meting van
de calcium score, maar aanvullende informatie kan uit deze scan worden verkregen,
zoals over het epicardiaal vetweefsel (EAT) en mediastinaal vetweefsel (MAT). EAT
en MAT kunnen worden gemeten met behulp van speciale softwareprogramma’s.
Meerdere studies hebben een verband aangetoond tussen EAT en ernstig coronairlij-
den, maar het is nog niet duidelijk of dit ten gevolge is van lokale of endocriene ef-
fecten. In een gelijkwaardige groep patiënten met bekend perifeer vaatlijden, is het te
verwachten dat het endocriene eﬀect van vetweefsel vergelijkbaar is. In deze patiën-
tengroep was een milde, maar positieve milde relatie tussen EAT en de aanwezigheid
van coronairlijden, die ook na correctie voor het lichaamsoppervlak aanwezig bleef
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(Hoofdstuk 5). Er is geen relatie gevonden tussen MAT en de aanwezigheid van
coronairlijden. Deze resultaten suggereren dat EAT een lokaal eﬀect heeft op coro-
naire atherosclerose, naast het endocriene eﬀect van visceraal vet. Deze voorlopige
resultaten geven aanleiding voor verder onderzoek.
Tenslotte werd in Hoofdstuk 6 een nieuwe niet-invasieve biomarker voor advanced
glycation endproducts met behulp van autoﬂuorescentie via de huid (skin AF) bestu-
deerd. Er bestaat een verband tussen skin AF en atherosclerose bij patiënten met
diabetes of nieraandoeningen. Er is echter nog nooit met behulp van niet-invasieve
beeldvorming onderzocht of skin AF ook al verhoogd is bij patiënten met subklinische
atherosclerose. In deze studie werden 223 personen onderzocht, waarbij de hoogte
van skin AF bij personen zonder subklinische atherosclerose werd vergeleken met
waardes in patiënten met atherosclerose, zonder en met klachten. Skin AF bleek
reeds verhoogd bij subklinische atherosclerose, onafhankelijk van bekende risicofac-
toren zoals diabetes en nierziekte. Verder was skin AF verhoogd in relatie tot de mate
van atherosclerose. Dit suggereert dat advanced glycation endproducts geassocieerd
kunnen zijn met de atheroscleroselast. Voordat deze techniek in de praktijk kan wor-
den toegepast voor primaire preventie, moeten de resultaten worden bevestigd in een
grote bevolkingsstudie.
In dit proefschrift zijn meerdere nieuwe biomarkers bestudeerd voor de detectie van
coronaire atherosclerosis. Deze resultaten kunnen richting geven aan verdere klinische
studies en gerandomiseerde trials. Het is te verwachten dat cCTA, eventueel met
aanvullende niet-invasieve biomarkers dienen als een one-stop shop voor de detectie
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mensen vergeten zijn, dan ook alvast bij deze hartelijk bedankt voor jullie hulp.
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statistiek was dit ook allemaal niet mogelijk geweest.
Belangrijke personen om niet te vergeten zijn mijn kamergenoten, Hendrik en Petra,
met wie ik 4 jaar lang lief en leed gedeeld heb. We hebben achter die immer gesloten
deur gelachen en gehuild. Hendrik, als het weer eens tegen zat, hebben we gezamen-
lijk tegen elkaar kunnen klagen over hoe zwaar het wel niet was. Toen je je ontslag
in wilde dienen, hebben Petra en ik je proberen te overtuigen om dit niet te doen. Ik
ben blij dat je het inderdaad niet gedaan hebt, en dat we nu samen bezig zijn met de
opleiding tot radioloog. Petra, ook wij hebben lange gesprekken gehad, zowel over
promotiegerelateerde als persoonlijke onderwerpen. Hier heb ik veel steun aan gehad,
en ik hoop jij ook. Ik ben dankbaar voor de vele keren dat je me hebt bijgestaan als
ik weer eens vastliep met het onderzoek. Helaas heb je er voor gekozen om niet met
ons de opleiding te gaan volgen. Ik hoop dat je uiteindelijk vindt wat je wilt gaan
doen.
Ook met mijn andere collega’s op de G2 heb ik een goede tijd gehad. Hildebrand,
Volkan, Astri, Wisnu, Gert Jan, Marjolein, Peter, Paul en Jolanda, we hebben veel
kunnen lachen op de afdeling. Tenminste, als de deur eindelijk een keer open was.
Ik realiseer me dat we ons soms een beetje van de rest van de afdeling hebben
afgezonderd. . . Tijdens de congressen hebben we ons wel kunnen vermaken.
Karolien, natuurlijk ben ik jou niet in het rijtje vergeten, maar ik wil je graag extra
bedanken. Zonder je hulp en voorbeeldbestanden had ik me nooit door die LATEX
handleiding heen kunnen worstelen.
Als laatste wil ik de belangrijkste persoon in mijn leven bedanken. Lieve Esther, jij
hebt me het allerbelangrijkste gegeven om alles vol te kunnen houden, onze dochters
Renske en Myrthe. Ik weet niet wat er gebeurd zou zijn zonder jouw eeuwige steun
en geduld. Ik weet dat je veel met me te stellen hebt gehad, en dat ik veel te weinig
tijd voor je gehad heb. Ik hoop dat er dadelijk weer een stijgende lijn in zit en dat
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